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ABSTRACT
The attempted formation of co-crystals with a series of cyclotriphosphazene derivatives has been investigated. Despite numerous
attempts, only one co-crystal was obtained. The crystal structure of this material, [hexakis(4-pyridyloxy)-cyclotriphos-
phazene][terephthalic acid]2.5, is presented here. The crystal structures of 2,2-bis(4-formylphenoxy)-4,4,6,6-bis[spiro(2’,2”-dioxy-
1’,1”-biphenylyl]cyclo-triphosphazene and hexakis(4-cyanophenoxy)cyclotriphosphazene are also reported for the first time.
The extremely low rate of co-crystal occurrence in these materials cannot be explained, despite the consideration of several possi-
bilities. This serves as a cautionary tale – co-crystal formation is not necessarily straightforward.
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1. Introduction
Cyclophosphazenes, which are formally unsaturated com-
pounds containing alternating phosphorus-nitrogen bonds,1
have received much attention due to the wide range of possible
applications for these compounds.2 Cyclotriphosphazenes,
(R2PN)3, have received particular attention from the crystal
engineering community since the discovery of the remarkable
inclusion properties of tris(o-phenylenedioxy)cyclotriphos-
phazene (TPP).3 TPP is a highly robust host, forming inclusion
complexes in the solid state with a variety of solvents, whether it
is exposed to liquids or to solvent vapours.4 The high density,
nonporous structure of TPP has also been determined, and it has
been shown that under CO2 pressure the high density structure
can be transformed to the low density, porous structure.5 Not
only does this particular organic host include a wide variety of
small organic molecules, but it has also been shown to include
various polymers.6 We speculated that if TPP has the ability to
form such a broad range of inclusion compounds, the possibility
exists that other cyclotriphosphazene derivatives could also
form a range of interesting supramolecular assemblies – be they
inclusion compounds or co-crystals.7 It was therefore decided to
embark on a systematic investigation of co-crystal and solvate
formation with various cyclotriphosphazene derivatives.
Cyclotriphosphazenes are attractive targets for this kind of
systematic study due to the ease of synthesis of a variety of sub-
stituted derivatives from hexachlorocyclotriphosphazene,
(NPCl2)3.
2a,4c,8 Despite this, there have been few systematic crystal
engineering studies on cyclotriphosphazenes.9 Chandrasekhar
et al.9a used cyclotriphosphazenes and the principles of direc-
tional hydrogen bonding to design supramolecular assemblies
in the solid state. They specifically selected hydrazide deriva-
tives with the intent of using the terminal –NH2 groups as proton
donors and the phosphazene ring nitrogen atoms as proton
acceptors. This interaction results in the formation of a hexagonal
close-packed sheet in the case of N3P3[N(Me)NH2]6. When one of
the phosphorus atoms is substituted with a 2,2’-biphenol group
– spiro-N3P3[O2C12H8][N(Me)NH2]4 – it results in the formation of
a double chain through the hydrogen bonding of a ring nitrogen
atom to a N(Me)NH2 substituent. This is one of the few examples
of using tailored intermolecular interactions to direct the aggre-
gation of cyclotriphosphazenes.
There are also a number of known co-crystals containing a
cyclotriphosphazene derivative.10 One of the most interesting
co-crystals is that of hexakis(4-carboxyphenoxy)-cyclo-
triphosphazene with hexakis(4-pyridylcarbinoxy)cyclo-
triphosphazene (CSD refcode EZEJEY).11,12 Hydrogen bonds are
formed between the carboxylic acid and pyridyl groups on the
cyclotriphosphazenes. Due to the three-up and three-down
arrangement of the substituents on each cyclotriphosphazene,
they assemble to form columns in the crystal structure. Halogen
bonding between iodo-substituted perfluorocarbons and
pyridyl moieties has been successfully used to construct
co-crystals of cyclotriphosphazenes.10a,b One of these co-crystals
also forms a pillared structure due to the arrangement of the
cyclotriphosphazene substituents.10b These co-crystals served as
the inspiration to design similar pillared assemblies with differ-
ent cyclotriphosphazene derivatives.
We selected a number of substituted cyclotriphosphazenes
(Scheme 1) that have either the potential to form strong supra-
molecular synthons (hydrogen or halogen bonds), or have
awkward shapes, or both. We hoped that the flexibility and
awkward shape of these molecules in general might predispose
them to crystallize as solvates in the solid state. The co-formers
that were selected had the potential to form known supramo-
lecular synthons with the functional groups on the phosphazenes
(hydrogen bonds, halogen bonds, p–p interactions).
At the start of this investigation, it was anticipated that several
co-crystals would be obtained. Molecules and co-crystal formers
with the potential to form strong supramolecular synthons were
selected, and a thorough screen was planned. In general, publi-
cations involving co-crystal synthesis do not report problems
encountered in obtaining co-crystals. A close look at the most
recent papers in a top crystal engineering journal13 containing
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the word co-crystal (or cocrystal) in the title confirms this. One of
the studies discusses salt versus co-crystal formation, and it
appears multi-component crystals were obtained for all combi-
nations investigated.13c Four of the studies involve co-crystal
screens. In one screen it seems all combinations tried gave
co-crystals.13a In the other three screens, co-formers were chosen
so as to form strong intermolecular interactions. Two screens
had low rates of co-crystal formation (1 co-crystal from 8 combi-
nations13b and 4 co-crystals from 25 combinations13e), but make
no comment on this. The third screen found 4 co-crystals from
around 300 crystallizations.13d The researchers comment ‘The
scarcity of co-crystals of fenamic acid derivatives, as reported in
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Scheme 1
The cyclotriphosphazene derivatives investigated in this study.
this study and in previous literature, is due to both the strong
carboxylic acid homodimer synthon that is dominant within the
numerous polymorphs of the fenamic acid derivatives, and the
ability for the molecules to adopt several stable conformations of
their own. The strength of these interactions within these
systems results in the evident preferential formation of poly-
morphs over co-crystals.’
Some groups have reported investigations into why certain
co-crystals (or groups of co-crystals) do not readily form; how-
ever, these papers are few and far between.14 From the literature,
a newcomer to this field might expect that obtaining a co-crystal
is a relatively simple matter – as long as an appropriately strong
interaction could form between the two co-crystal formers, a
co-crystal will be isolated. The results of our extensive study,
reported herein, show that this is most certainly not always the
case.
2. Experimental
Cyclophosphazenes 1–12 were synthesized using established
literature procedures, with some adaptations where necessary.
Full details are given in the Supplementary material.
Almost 300 co-crystallization experiments were carried out in
this study. Details of these experiments are also given in full in
the Supplementary material. The choice of co-former was based
on the potential to form strong supramolecular synthons. For
example, phosphazenes containing pyridyl substituents were
co-crystallized with molecules containing carboxylic acids or
hydroxyl groups, in the hope that formation of a pyridyl...HO
hydrogen bond would drive co-crystal formation. We also inves-
tigated co-formers that might form p–p interactions or halogen
bonds. Finally, bulky or awkwardly-shaped molecules were also
investigated as co-formers. For lists of co-crystal formers and
solvates used, see Tables S1–S17 in the Supplementary material.
Very few mechanochemical experiments were carried out, as
this tended to result in degradation of the phosphazene ring,
most likely forming phosphazene polymers. There were no
issues with solubility of the phosphazenes used.
For the structures of 1, 5, and 10–12, X-ray intensity data were
collected on a Bruker-Nonius SMART Apex diffractometer
equipped with a fine-focus sealed tube and a 0.5 mm Monocap
collimator (monochromated Mo-Ka radiation, l = 0.71073 Å).
Data were captured with a CCD area-detector with the generator
powered at 40 kV and 30 mA. The temperature of the crystal was
controlled by constant stream of nitrogen gas produced by an
Oxford Cryosystems Cryostat (700 Series Cryostream Plus). For
the crystal structures of 6 and the co-crystal 7TPA, intensity
data were collected on a Bruker Apex DUO CCD diffractometer
with a multilayer monochromator. Mo-Ka radiation (l= 0.71073 Å)
was selected for the experiments. The temperature of the crystal
was controlled using an Oxford Cryosystems Cryostream. Data
reduction was done by means of a standard procedure using the
Bruker software package SAINT15 and the absorption corrections
and the correction of other systematic errors were performed
using SADABS.16 The structures were solved by direct methods
using SHELXS-97 and refined using SHELXL-97 and SHELXL-
2014/7.17 X-Seed18 was used as the graphical interface for the
SHELX program suite. Most hydrogen atoms were placed in
calculated positions using riding models. Hydrogen atoms on
nitrogen or oxygen atoms were located in the electron density
difference map and allowed to refine.
Cambridge Structural Database12 (CSD) searches were carried
out using ConQuest19 version 1.17 on version 5.36 with 3 updates
(Nov. 2014, Feb. 2015, May 2015).
For powder X-ray diffraction analysis, samples were ground to
a fine powder with a mortar and pestle and placed on a zero-
background sample holder. Experiments were carried out on a
PANalytical X’Pert PRO instrument in Bragg-Brentano geometry.
Intensity data were collected using an X’Celerator detector and
2q scans in the range of 5–50° were performed using Cu-Ka
radiation (l = 1.5418 Å).
Differential scanning calorimetry was carried out using a TA
Instruments Q100 system under an N2 gas purge, with a flow
rate of 50.0 ml min–1. The samples (ranging from 1.5 to 3 mg) were
placed in aluminium pans that were non-hermetically sealed
with vented aluminium lids. The heating rate for all experiments
was 10 °C min–1, and the cooling rate was 5 °C min–1.
3. Results and Discussion
3.1. CSD Analysis
In order to give some idea of the frequency with which
cyclotriphosphazenes form co-crystals or solvates, a Cambridge
Structural Database search was carried out.12 If the search is
restricted to ‘organic only’ structures with 3D co-ordinates
determined, 728 structures containing the cyclotriphosphazene
moiety are identified. Of these, 26 are salts or zwitterions (identi-
fied by searching for any charged atom). These were removed
(as salts are necessarily multi-component crystals). Of the remain-
ing 702 structures, only 109, or 15.5 %, are multi-component
crystals (>1 chemical residues). This is only slightly lower than
the occurrence in the CSD as a whole, where 16.8 % (42 601/252
827) of non-ionic organic structures are multi-component crystals.
These results imply that co-crystal or solvate formation is no
more or less likely to occur with cyclotriphosphazenes than with
any other molecule.
3.2. Co-crystallization Experiments
3.2.1. Co-crystallizations with 1
The choice of 1 as a potential co-crystal former was based on its
paddlewheel conformation, which indicated that it may form
inclusion compounds similar to those formed by TPP.3,4,5,6 The
NH-functional groups on 1 are also available as potential
hydrogen bond donors. A number of co-crystallization experi-
ments were carried out with 1 (Table S1). Only the crystallization
from THF/hexane yielded crystals. These proved to be the
known hydrate of 1 (CSD refcode COPVAE).20 We have
re-determined this structure at 173 K, and crystallographic data
are given in Table 1. El Murr et al.20 report the isolation of crystals
of non-solvated 1 from the reaction mixture, but these crystals
did not survive exposure to X-rays. However, the crystals grown
from methanol that incorporated water into the structure did
not disintegrate upon exposure to X-rays, suggesting that incor-
poration of water increases the stability of the crystal. It seemed
likely that other hydrogen bonding solvents might also fulfil this
role, and we therefore attempted crystallization from a number
of hydrogen bonding solvents (donors and acceptors, see
Table S1) in the hope of forming solvates. This was unsuccessful.
3.2.2. Co-crystallization Experiments with 2, 3 and 4
Numerous attempts to generate either solvates or co-crystals
with 2, 3 and 4 were made (see Tables S2, S4 and S6 in the Supple-
mentary material). None of these experiments yielded
multi-component crystals. In most cases either no crystals were
obtained, or crystals of the starting materials were obtained.
In order to investigate whether additional energy might be
required for co-crystal formation, mechanochemical experi-
ments were carried out with 2, 3 and 4. These derivatives were
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ground together with 4,4’-bipyridine, imidazole or benzimidazole
(Tables S3, S5, S7). The products obtained on grinding both 2 and
3 with imidazole were sticky white substances, whereas all the
other products were fine dry powders. The products of the
grinding experiments were analysed by PXRD, which showed
that all products consisted of physical mixtures of the reagents
(see Supplementary material).
The product obtained by grinding 2 with benzimidazole was
dissolved in THF. This yielded a pink precipitate with a powder
pattern that differs from those of both 2 and benzimidazole.
NMR analysis of this precipitate showed numerous signals in
the 31P spectrum that do not correspond with those normally
observed for 2. This could indicate that grinding the two compo-
nents together resulted in substitution of the chloro groups on
the cyclotriphosphazene ring, or that the cyclotriphosphazene
ring has opened and polymerized. The material is clearly not a
co-crystal of 2.
3.2.3. Crystal Structures of 5 and 6
Co-crystallization experiments were carried out with 5 in the
expectation that the awkward shape of the molecule might
cause inefficient packing in the solid state, resulting in inclusion
of solvent molecules. Attempts were therefore made to crystal-
lize 5 from a variety of solvents (Table S8). This yielded crystals of
5 in two cases (benzene and acetone). As the crystal structure of
this material has not previously been reported, it is described
here. Selected crystallographic data are given in Table 1.
Compound 5 crystallizes in the monoclinic space group P21/n.
One of the benzaldehyde groups is disordered over two positions
of approximately equal occupancy. The molecules form discrete
dimers via an offset face-to-face interaction between benzaldehyde
groups, and the dimers are arranged in chains with p-stacking
interactions between the biphenyl groups (Fig. 1). There are no
hydrogen bonds evident in the structure, confirming that the
aldehyde moiety is not a particularly strong hydrogen bond
acceptor. Despite this, 5 was co-crystallized with a wide range of
hydrogen bond donors. These co-crystallization experiments
are listed in Table S9 in the Supplementary material. The ratio of
5 to co-crystal former was 1:2 in most experiments in order to
take into account the two aldehyde moieties that could poten-
tially participate in hydrogen bonding interactions. None of
these experiments yielded any co-crystals. Some crystallizations
produced crystals of 5, some produced crystals of the co-formers
and some yielded no crystals at all.
Compound 6 was chosen for its potential to form supramo-
lecular synthons through the nitrile functionality. It is sparingly
soluble in most solvents, except for DMSO and DMF in which it
readily dissolves. Several co-crystallization experiments were
carried out with halogen-containing co-crystal formers (see
Table S10); however, no co-crystals were obtained. Rod-shaped
crystals of pure 6 were grown from a co-crystallization experi-
ment with bromopentafluorobenzene in DMSO. Selected crys-
tallographic details are given in Table 1.
Cyclophosphazene 6 crystallizes in P-1, with one molecule in
the asymmetric unit. Two cyanophenyl moieties are approxi-
mately parallel to one another above the plane of the phospha-
zene ring, and another two below the plane of the ring are also
approximately parallel to one another. The other two cyano-
phenyl moieties are twisted away from one another (Fig. 2a). The
molecules stack on top of one another to give columns parallel to
the crystallographic c axis (Fig. 2b). These columns pack along-
side one another in a slightly offset fashion. There are no imme-
diately apparent structure-directing intermolecular interactions
in this structure.
3.2.4. Co-crystallization Experiments with 7 and 8
Both 7 and 8 were chosen as possible co-crystal formers
because of the potential for hydrogen bond formation with
either the pyridyl or the hydroxyl functionality on the mole-
cules. One of the few known cyclotriphosphazene co-crystals
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Table 1 Selected crystal data for several cyclotriphosphazene derivatives.
1 5 6 7TPA 9á 21 10 11 12
Ratio 1:2 – – 1:2.5 – – – –
(phosphazene: other)
Chemical formula C9H28N9O2P3 C38H26N3O8P3 C42H24N9O6P3 C50H39N9O16P3 C36H24F6N3O6P3 C36H24Cl6N3O6P3 C36H24Br6N3O6P3 C36H24I6N3O6P3
Formula weight/ 387.31 745.53 843.61 1114.81 801.49 900.19 1166.95 1448.89
g mol–1
Crystal system Triclinic Monoclinic Triclinic Triclinic Monoclinic Monoclinic Orthorhombic Monoclinic
Space group P-1 P21/n P-1 P-1 P21/n P21/n Pnma P21/c
Z 4 4 2 2 4 4 4 4
a/Å 11.342(6) 10.897(2) 12.004(1) 7.943(4) 20.323(2) 17.642(1) 31.460(3) 13.472(1)
b/Å 11.374(6) 15.131(2) 12.315(1) 13.238(6) 8.051(8) 7.503(5) 13.367(1) 9.396(9)
c/Å 14.515(8) 20.907(3) 13.970(1) 23.627(1) 21.694(2) 27.914(2) 9.122(7) 32.635(3)
a/° 76.12(1) 90 80.628(2) 76.504(1) 90 90 90 90
b/° 76.43(1) 103.440(2) 80.015(2) 80.357(1) 103.831(1) 91.899(1) 90 96.230(1)
g/° 86.69(1) 90 71.023(1) 85.375(1) 90 90 90 90
Calculated 1.456 1.477 1.466 1.556 1.545 1.619 2.021 2.343
density/g cm–3
Cell volume/Å 3 1767.2(2) 3352.8(9) 1910.8(3) 2379.5(2) 3446.6(6) 3692.7(4) 3836.1(5) 4106.7(7)
Temperature/K 173(2) 100(2) 100(2) 100(2) 100(2) 103(2) 173(2) 100(2)
µ/mm–1 0.360 0.239 0.220 0.212 0.258 0.648 6.456 4.704
Independent 7360 3978 10363 11875 8117 6518 3514 7268
reflections
Rint 0.0153 0.0519 0.0454 0.0325 0.0290 0.0239 0.0550 0.0235
R1 [I > 2(I)] 0.0366 0.0601 0.0402 0.0374 0.0344 0.0281 0.0299 0.0309
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Figure 2 Packing in 6. (a) Orientation of the cyanophenyl moieties in 6. (b) Columns of molecules formed in 6.
Figure 1 Packing in 5. (a) The benzaldehyde moieties form discrete dimers via an offset face-to-face interaction. The structure can be viewed as
though the dimers form chains as shown in (b), indicated by the blue dotted lines. This is viewed down the crystallographic a axis. The chains then
close-pack as shown in (c), with close contacts between the biphenyl-2,2’-diol groups.
not based on TPP contains hexakis(4-pyridylcarbinoxy)cyclo-
triphosphazene, which is closely related to 7 (although the 3-D
coordinates for this co-crystal structure are not in the CSD).
Compound 7 therefore seemed a particularly promising candi-
date for co-crystal formation.
Numerous co-crystallization experiments were carried out
with both 7 and 8 (Tables S11 and S12 in the Supplementary
material). No co-crystals containing 8 were isolated. However,
7 was found to form a co-crystal with terephthalic acid, 7TPA.
Crystallographic data are given in Table 1.
The crystals of 7TPA were grown from a 1:2 ratio of
7:terephthalic acid in a layered solution of chloroform and DMF.
Crystals of 7 were dissolved in chloroform and the terephthalic
acid in DMF. Care had to be taken to add the two solutions
together slowly as terephthalic acid is insoluble in chloroform
and precipitates out of solution when chloroform is added to
DMF. The co-crystal, which contains 2.5 terephthalic acid mole-
cules for every molecule of 7, crystallizes in P-1. No charge trans-
fer has taken place, i.e. both carboxylic acid groups of each
terephthalic acid molecule are protonated, and these form
hydrogen bonds with the pyridyl groups on the cyclotriphos-
phazene. Five of the six pyridyl groups on the cyclotriphos-
phazene ring are involved in hydrogen bonding with a
terephthalic acid molecule through a COOH···N interaction
with the hydroxyl group of the carboxylic acid. This results in an
infinite hydrogen-bonded chain (Fig. 3a). The terephthalic acid
molecules shown in orange in Fig. 3b link neighbouring chains
through hydrogen bonding to a pyridyl group in the next chain.
It seems likely that the hydrogen bonds between 7 and
terephthalic acid are strong interactions, driving the formation
of a co-crystal. It is surprising, however, that no other co-crystals
with di-acids were isolated with this derivative despite this
seemingly strong interaction. This could indicate that the correct
shape match is very important in forming co-crystals with
cyclotriphosphazenes.
3.2.5. Co-crystallization Experiments with 9–12
The hexakis(4-halophenoxy)cyclotriphosphazene derivatives
9–12 were synthesized in order to investigate whether
co-crystals could be formed using supramolecular synthons
involving halogens. These derivatives were co-crystallized with
a range of small molecules, including molecules containing
halogens, nitriles and nitrogen-containing heterocycles such as
pyridine. The solvent systems that were used include acetonitrile,
acetonitrile/DCM, DCM, THF, THF/methanol, chloroform,
chloroform/acetone and DMSO, as well as combinations of these
solvents (Tables S13–16). In each case the cyclotriphosphazene
derivative crystallized as the pure material, rather than co-
crystallizing with other small molecules.
The crystal structures of 9–12 were originally determined at room
temperature.20 Our previous observation of polymorphism in 921
led us to redetermine the structures at 100 K, and the data are
included here for completeness (see Table 1). On analysis of the
crystal structures of these derivatives, it is apparent that
hexakis(4-fluorophenoxy)cyclotriphosphazene (9) and hexa-
kis(4-chlorophenoxy)cyclotriphosphazene (10) are isostruc-
tural, and that hexakis(4-bromophenoxy)cyclotriphosphazene
(11) and hexakis(4-iodophenoxy)cyclotriphosphazene (12) are
isostructural. The only differences between the structures are
slight changes in the twist of the phenoxy rings between deriva-
tives. DSC was also carried out on 9–12, but only 9 showed any
evidence of polymorphism in the temperature range investi-
gated.
The isostructurality between 9 and 10, as well as 11 and 12,
implied that combinations of these molecules may lead to
co-crystal formation. Unfortunately, co-crystals of 9 with 10, or
11 with 12, could not be grown from solution. The growth of
co-crystals by melting the isostructural compounds together
was then investigated (Table S17). Crystals of 9 and 10 were
ground together in a 1:1 ratio, melted and DSC analysis was per-
formed on the product. DSC analysis showed that the melting
point of the product (referred to as 9/10) is at 122.9 °C, which is
lower than the melting point of both 9 (129 °C) and 10 (152 °C).
The same procedure was followed for 11 and 12, and again there
is only one melting point at 173.1 °C. The melting point of 11 is
176.8 °C and that of 12 is 187.6 °C. This is, however, not conclusive
evidence that a co-crystal has formed.
PXRD analysis was carried out on the melt products 9/10 and
11/12. The results are shown in Fig. 4. PXRD analysis is unfortu-
nately also not conclusive. In both cases, the powder patterns of
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Figure 3 (a) The infinite hydrogen-bonded chain formed in 7TPA. (b) The hydrogen-bonded chains are linked via a terephthalic acid molecule,
shown here in orange, that hydrogen bonds to the pyridyloxy group of a neighbouring cyclotriphosphazene molecule.
the melt products largely correspond to the simulated patterns of
the halophenoxy derivatives. There are minor differences
between the patterns, but it is difficult to determine whether a
novel co-crystal has in fact formed. It is likely that any co-crystals
formed would be isostructural to the co-crystal formers, and
hence have similar powder patterns. The melt products could
also be solid solutions, as opposed to stoichiometric co-crystals.
We are thus unable to state conclusively whether these deriva-
tives form co-crystals from the melt.
3.3. Lack of Co-crystal Formation
During this investigation, a total of nearly 300 co-crystal-
lization experiments were carried out using 12 different
cyclophosphazene derivatives and a number of crystallization
techniques, and only one co-crystal was obtained. Largely, the
crystals that were obtained were of the pure cyclotriphos-
phazene derivative, with only one derivative (1) crystallizing as
a hydrate and no derivatives crystallizing as solvates. This is a
remarkably low success rate – the CSD study indicates that
around 15 % of cyclotriphosphazene-containing structures are
multi-component crystals. Why then was our success rate so
low?
The most obvious explanation is that the supramolecular
synthons employed were simply not strong enough to promote
co-crystallization, i.e. the heteromeric interactions were not as
strong as the homomeric interactions. This may well have been
the case for many of the combinations that were attempted,
although in a number of the molecules selected there are no
obvious strong intermolecular interactions in the crystals of the
pure material. However, this does not explain why a co-crystal
could be formed between 7 and terephthalic acid, but not
between 7 and any other carboxylic acids, despite numerous
attempts.
Inspection of the pKa values of the acids used (Table 2)
22
indicates that this is not simply a case of acid strength (and by
extension hydrogen bond strength). There are clearly other
factors involved.
It does appear that the size and shape of the co-crystallization
agent plays a role. A study conducted by Anderson et al.23 found
that molecules that crystallize with Z’ > 1 are generally
small, awkwardly shaped molecules. They are also more
conformationally restricted, which might explain why the
cyclotriphosphazenes seldom co-crystallize with smaller mole-
cules: cyclotriphosphazenes are much larger molecules with
substituents that are more conformationally flexible. It has also
been suggested that polymorphic molecules make better
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Figure 4 (a) PXRD analysis of the melt product 9/10. The pattern of 9/10 corresponds with the patterns of 9 and 10 to a large extent, but the results are
not conclusive. (b) PXRD analysis of the melt product of 11/12.
co-crystal formers.24 We do not observe this: compound 9 is
highly polymorphic, with four known polymorphs, yet no
co-crystals of this molecule were isolated. In this case, the
conformational flexibility of the molecule results in it crystalliz-
ing in a number of ways – the molecule can solve the problem of
close-packing without the need for a co-former. In order to
improve the probability of obtaining co-crystals or solvates with
cyclotriphosphazenes, the substituents on the P-N ring should
be conformationally restricted (no flexible O linkage). Func-
tional groups on the substituents should be strong hydrogen
bond donors or acceptors, or strong halogen bond acceptors
(such as iodine where the acceptor strength has been increased
by fluorination).
This study aimed to isolate co-crystals from solution, in the
manner one might carry out a co-crystal screen for a pharmaceu-
tical molecule. The difficulty encountered in obtaining
co-crystals was not at all anticipated. It is possible that with
further detailed investigation, the particular conditions to form
co-crystals of these molecules could be identified. Several
avenues were pursued to try and explain the low success rate,
including analysis of what preferred co-crystal formers might
be. None of these offered any insight – in fact, all analysis indi-
cated that we should be able to form other co-crystals with 7. It is
particularly interesting that no further co-crystals between 7 and
carboxylic acids were obtained. No obvious explanation for this
can be identified.
4. Conclusions
An extensive investigation of co-crystal formation with 12
cyclotriphosphazene derivatives has been carried out. Around
300 co-crystallization experiments were carried out, but only
one co-crystal was obtained. These results clearly indicate that
many cyclotriphosphazenes have a very low tendency to form
co-crystals. There is no clear explanation for this, but it serves as a
caution: the formation of co-crystals is not necessarily trivial,
and certainly more investigation is needed to shed light on why
this is the case.
Acknowledgements
We thank the National Research Foundation* of South Africa,
Stellenbosch University and the SU Department of Chemistry
and Polymer Science for funding.
Supplementary Material
Details of co-crystallization experiments, PXRD, NMR, DSC
and synthetic details are available as supplementary informa-
tion. X-ray crystallographic data are available in cif format.
CCDC 1055282-1055288 contain the crystallographic data for
this manuscript. These data can be obtained free of charge
from The Cambridge Crystallographic Data Centre via
www.ccdc.cam.ac.uk/data_request/cif.
References and Notes
1 N.N. Greenwood and A. Earnshaw, Chemistry of the Elements, 2nd
edn., Pergamon Press, Great Britain, 1997.
2 (a) M. Gleria and R.J. De Jaeger, Aspects of phosphazene research,
J. Inorg. Organomet. Polym., 2001, 11, 1–45. (b) R. De Jaeger and M.
Gleria, Poly(organophosphazene)s and related compounds: synthe-
sis, properties and applications, Prog. Polym. Sci., 1998, 23, 179–276.
3 H.R. Allcock, Phosphonitrilic compounds. II. Reactions of phospho-
nitrilic chlorides with catechol and triethylamine, J. Am. Chem. Soc.,
1964, 86, 2591–2595.
4 (a) H.R. Allcock, R.W. Allen, E.C. Bissell, L.A. Smeltz and M. Teeter,
Phosphorus-nitrogen compounds. 26. Molecular motion and molec-
ular separations in cyclophosphazene clathrates, J. Am. Chem. Soc.,
1976, 98, 5120–5125. (b) H.R. Allcock, M.L. Levin and R.R. Whittle,
R.R., Tris(o-phenylenedioxy)cyclotriphosphazene: the clathration-
induced monoclinic to hexagonal solid-state transition, Inorg. Chem.,
1986, 25, 41–47. (c) G. Couderc and J. Hulliger, Channel forming
organic crystals: guest alignment and properties, Chem. Soc. Rev.,
2010, 39, 1545–1554.
5 J. Tian, P. Thallapally, J. Liu, G.J. Exarhos and J.L. Atwood, Gas-
induced solid state transformation of an organic lattice: from non-
porous to nanoporous, Chem. Commun., 2011, 47, 701–703.
6 (a) H.R. Allcock, A.P. Primrose, N.J. Sunderland, A.L. Rheingold, I.A.
Guzei and M. Parvez, Inclusion of polymers within the crystal struc-
ture of tris(o-phenylenedioxy)cyclotriphosphazene, Chem. Mater.,
1999, 11, 1243–1252. (b) S. Bracco, A. Comotti, P. Valsesia, M. Beretta
and P. Sozzani, Self-assembly of 1,4-cis-polybutadiene and an
aromatic host to fabricate nanostructured crystals by CH...p interac-
tions, CrystEngComm, 2010, 12, 2318–2321.
7 We take co-crystal to imply any multi-component crystal where the
components occur in a stoichiometric ratio, and are neutral. Solvates
are included in this definition, but we refer to what are convention-
ally called solvates as such to avoid confusion.
8 (a) H.R. Allcock, Recent advances in phosphazene (phosphonitrilic)
chemistry, Chem. Rev., 1972, 72, 315–356; V. Chandrasekhar, P. Thilagar
and B.M. Pandian, Cyclophosphazene-based multi-site coordination
ligands, Coord. Chem. Rev., 2007, 251, 1045–1074. (b) A. Steiner, Supra-
molecular structures of cyclotriphosphazenes, in Polyphosphazenes for
Biomedical Applications, John Wiley & Sons, 2008, pp. 411–453.
9 (a) V. Chandrasekhar, V. Krishnan, G.T.S. Andavan, A. Steiner and S.
Zacchini, Cyclophosphazene supramolecular assemblies: N-H–-N
and C-H–-N mediated supramolecular networks in the crystal struc-
tures of N3P3[N(Me)NH2]6 and spiro-N3P3[O2C12H8][N(Me)NH2]4,
CrystEngComm. 2003, 5, 245–247. (b) V. Chandrasekhar, P. Thilagar, V.
Krishnan, J.F. Bickley and A. Steiner, Click synthesis of fluorine-rich
cyclotriphosphazene hydrazones. synthesis and supramolecular
structures of N3P3(N(Me)N=CHC6F5)6, spiro-N3P3(C12H8O2)
(N(Me)N=CHC6F5)4, and dispiro-N3P3(C12H8O2)2(N(Me)N=
CHC6F5)2, Cryst. Growth Des., 2007, 7, 668–675.
10 (a) R. Bertani, E. Ghedini, M. Gleria, R. Liantonio, G. Marras, P.
Metrangolo, F. Meyer, T. Pilati and G. Resnati, Cyclotriphosphazene
[N3P3(2,2’-dioxybiphenyl)2-(4-pyridinoxy)2] and its halogen bonded
complex with 1,4-diiodotetrafluorobenzene, CrystEngComm, 2005, 7,
511–513. (b) R. Bertani, F. Chaux, M. Gleria, P. Metrangolo, R. Milani,
T. Pilati, G. Resnati, M. Sansotera and A. Venzo, Supramolecular rods
via halogen bonding-based self-assembly of fluorinated
phosphazene nanopillars, Inorg. Chim. Acta, 2007, 360, 1191–1199. (c)
T. Itaya, N. Azuma and K. Inoue, Self-Assembly of hexakis(4-pyridyl-
methoxy)cyclotriphosphazene and 1,4-anthracenedicarboxylic acid:
structure and inclusion behavior, Bull. Chem. Soc. Jpn., 2002, 75,
2275–2281.
11 K. Inoue, T. Itaya and N. Azuma, Self-assembly through hydrogen
bonding of cyclotriphosphazenes. Formation of cylindrical struc-
tures, Supramol. Sci., 1998, 5, 163–166.
12 F.H. Allen, The Cambridge Structural Database: a quarter of a million
crystal structures and rising, Acta Crystallogr., Sect. B: Struct.
Crystallogr. Cryst. Chem., 2002, 58, 380–388. Reference 11 reports on
RESEARCH ARTICLE H. Wahl, D.A. Haynes and T. le Roex 42
S. Afr. J. Chem., 2016, 69, 35–43,
<http://journals.sabinet.co.za/sajchem/>.
* This material is based upon work supported financially by the National Research
Foundation of South Africa. Any opinion, findings and conclusions or recommendations
expressed in this material are those of the authors and therefore the NRF does not accept
any liability in regard thereto.
Table 2 pKa values of various carboxylic acids.
Acid pKa
21
Adipic acid 4.41, 5.41
Citric acid 3.13, 4.76, 6.40
Fumaric acid 3.02, 4.38
Isophthalic acid 3.70, 4.60
Maleic acid 1.92, 6.23
Malic acid 3.40, 5.11
Pamoic acid 2.51, 3.10
Succinic acid 4.21, 5.64
Tartaric acid (DL) 3.03, 4.37
Terephthalic acid 3.54, 4.34
Trimesic acid 3.12, 3.89, 4.70
interactions in the crystal structure. There are however no 3D-coor-
dinates for this structure in the Cambridge Structural Database.
13 Search was carried out on 31 August 2015 in CrystEngComm. A total of
eleven papers with a 2015 date were identified. Six of these discuss
only a single new co-crystal, with no screening carried out. These are
not included here.
(a) A. Jacobs and F.M. Amombo Noa, Co-crystals and co-crystal hy-
drates of vanillic acid, CrystEngComm, 2015, 17, 98–106. (b) Y. Yan,
J.-M. Chen and T.-B. Lu, Thermodynamics and preliminary pharma-
ceutical characterization of a melatonin–pimelic acid cocrystal pre-
pared by a melt crystallization method, CrystEngComm, 2015, 17,
612–620. (c) A. Lemmerer, S. Govindraju, M. Johnston, X. Motloung
and K.L. Savig, Co-crystals and molecular salts of carboxylic
acid/pyridine complexes: can calculated pKa’s predict proton trans-
fer? A case study of nine complexes, CrystEngComm, 2015, 17,
3591–3595. (d) K. E. Wittering, L. R. Agnew, A. R. Klapwijk, K. Robert-
son, A.J.P. Cousen, D.L. Cruickshank and C.C. Wilson, Crystallisation
and physicochemical property characterisation of confor-
mationally-locked co-crystals of fenamic acid derivatives,
CrystEngComm, 2015, 17, 3610–3618. (e) A. S. Sinha, U. B. Rao
Khandavilli, E.L. O’Connor, B.J. Deadman, A.R. Maguire and S.E.
Lawrence, Novel co-crystals of the nutraceutical sinapic acid,
CrystEngComm, 2015, 17, 4832–4841.
14 See for example (a) N. Báthori, A. Lemmerer, G.A. Venter, S.A. Bourne
and M.R. Caira, Pharmaceutical co-crystals with isonicoti-
namide-vitamin B3, clofibric acid, and diclofenac – and two
isonicotinamide hydrates, Cryst. Growth Des., 2011, 11, 75–87. (b)
D.-K. Buçar, G.M. Day, I. Halasz, G.G.Z. Zhang, J.R.G. Sander, D.G.
Reid, L.R. MacGillivray, M.J. Duer and W. Jones, The curious case of
(caffeine)(benzoic acid): how heteronuclear seeding allowed the
formation of an elusive co-crystal, Chem. Sci., 2013, 4, 4417–4425. (c)
M.A. Solomos, C. Mohammadi, J.H. Urbelis, E.S. Koch, R. Osborne,
C.C. Usala and J.A. Swift, Predicting cocrystallization based on
heterodimer energies: the case of N,N’-diphenylureas and triphenyl-
phosphine oxide, Cryst. Growth Des., 2015, 15, 5068–5074.
15 SAINT Data Reduction Software, Version 6.45; Bruker AXS Inc., Madi-
son, WI, 2003.
16 (a) SADABS, Version 2.05; Bruker AXS Inc., Madison, WI, 2002. (b) R.
H. Blessing, An empirical correction for absorption anisotropy, Acta
Crystallogr., Sect. A: Found. Crystallogr., 1995, 51, 33–38.
17 G.M. Sheldrick, A short history of SHELX, Acta Crystallogr., Sect. A:
Found. Crystallogr., 2008, 64, 112–122.
18 L.J. Barbour, X-Seed—A software tool for supramolecular crystallog-
raphy, J. Supramol. Chem., 2001, 1, 189–191.
19 I.J. Bruno, J. C. Cole, P.R. Edgington, M. Kessler, C.F. Macrae, P. McCabe,
J. Pearson and R. Taylor, New software for searching the Cambridge
Structural Database and visualising crystal structures, Acta
Crystallogr., Sect. B: Struct. Crystallogr. Cryst. Chem., 2002, 58, 389–397.
20 N. El Murr, R. Lahana, J.-F. Labarre and J.-P. Declercq, An answer to
the spiro versus ANSA dilemma in cyclophosphazenes: Part V. The
dispiro N3P3Cl2 [HN-(CH2)3,4-NH]2 and trispiro N3P3 [HN-(CH2)3-
NH]3 derivatives, J. Mol. Struct., 1984, 117, 73–85.
21 H. Wahl, D.A. Haynes and T. le Roex, A series of polymorphs of
hexakis(4-fluorophenoxy)cyclotriphosphazene, Cryst. Growth Des.,
2012, 12, 4031–4038.
22 (a) D.R. Lide, Editor-in-Chief, CRC Handbook of Chemistry and Physics,
CRC Press, Boca Raton, FL, 88th edn, 2008. (b) H.C. Brown, D.H.
McDaniel and O. Häfliger, in Determination of Organic Structures by
Physical Methods, (E.A. Braude and F.C. Nachod, eds.), Academic
Press, New York, 1955. (c) Handbook of Pharmaceutical Salts: Properties,
Selection and Use, (P.H. Stahl and C.G. Wermuth, eds.), Wiley-
VCH/VHCA, Weinheim/Zürich, 2002.
23 K.M. Anderson, M.R. Probert, A.E. Goeta and J.W. Steed, Size does
matter—the contribution of molecular volume, shape and flexibility
to the formation of co-crystals and structures with Z’ > 1,
CrystEngComm, 2011, 13, 83–87.
24 C.B. Aakeröy and D.J. Salmon, Building co-crystals with molecular
sense and supramolecular sensibility, CrystEngComm, 2005, 7,
439–448.
RESEARCH ARTICLE H. Wahl, D.A. Haynes and T. le Roex 43
S. Afr. J. Chem., 2016, 69, 35–43,
<http://journals.sabinet.co.za/sajchem/>.
S1 
 
Lack of co-crystal formation with cyclotriphosphazenes: a cautionary tale 
Helene Wahl, Delia A. Haynes* and Tanya le Roex 
Department of Chemistry and Polymer Science, University of Stellenbosch, P. Bag X1, Matieland, 7602, Republic 
of South Africa. E-mail: dhaynes@sun.ac.za
 
 
 
 
Supporting Information 
 
List of cyclotriphosphazenes       S1 
Co-crystallisation experiments       S3 
Synthesis of 1-12        S21 
References         S24 
 
 
 
  
S2 
 
 
Scheme S1 The cyclotriphosphazenes investigated in this work. 
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Co-crystallisation experiments 
The components of each crystallisation experiment (see Tables S1, S2, S4, S6, S8-14) were dissolved 
in the appropriate solvent with gentle heat and stirring. In cases where there were still undissolved 
particles, the solution was filtered through a non-sterile 33 mm Millex-HV syringe filter unit into a 
glass vial. All solutions were left to stand at room temperature and crystals were formed either via 
slow evaporation of the solvent, vapour diffusion of one solvent into another or solutions were layered 
with a second solvent to induce crystal formation at the interface of the two solutions. 
 
Table S1 Co-crystallisation experiments carried out with 1. All crystallisations were carried out via 
slow evaporation. Crystals obtained were that of the known hydrate of 1 (CSD-COPVAE) or no 
product was obtained. 
Co-former 
Quantity (1; co-
former) /mg 
Mole ratio  
(1:co-former) 
Solvent system Product 
isophthalic acid 29; 14 1:1 methanol none 
terephthalic acid 15; 15 1:2 methanol terephthalic acid 
trimesic acid 29; 20 1:1 methanol none 
succinic acid 14; 15 1:3 methanol none 
maleic acid 13; 13 1:3 methanol/THF none 
tartaric acid 13; 12 1:3 methanol none 
2,6-naphthalene 
dicarboxylic acid 
29:18 1:1 methanol 
2,6-naphthalene 
dicarboxylic acid 
solvent - - THF none 
solvent - - hexane/THF known COPVAE 
solvent - - DCM none 
solvent - - DMSO none 
solvent - - acetonitrile known COPVAE 
solvent - - methanol none 
solvent - - ethanol none 
solvent - - DMF none 
solvent - - NMP none 
solvent - - chloroform none 
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Table S2 Co-crystallisation experiments carried out with 2. All crystallisations were carried out via 
slow evaporation. In some cases crystals of the starting materials were obtained, otherwise no crystals 
were obtained. 
Co-former 
Quantity (2; co-
former) /mg 
Mole ratio (2:co-
former) 
Solvent system Product 
DCM 50 As solvent - none 
benzene 45 As solvent - none 
toluene 46 As solvent - none 
chloroform 54 As solvent - none 
acetonitrile 49 As solvent - none 
pyridine 48 As solvent - none 
1,4-dioxane 55 As solvent - none 
NMP 51 As solvent - none 
THF 74 As solvent - none 
DMF 68 As solvent - none 
isophthalic acid 53; 41 1:2 DCM/THF none 
imidazole 55; 25 1:3 DCM/THF none 
benzimidazole 59; 33 1:3 DCM/THF 
benzimidazole 
hydrate 
4,4'-bipyridine 52; 35 1:2 DCM/THF none 
benzonitrile 54 As solvent - none 
3,4-lutidine 62; 35 1:3 DCM none 
 
Table S3 Mechanochemical experiments carried out with 2. Samples were ground by hand in a mortar 
and pestle for approximately 5 minutes, yielding homogenous powders. 
Co-former 
Quantity (2; co-former) 
/mg 
Mole ratio (2: co-
former) 
4,4'-bipyridine 28; 32 1:2 
imidazole 56; 24 1:2 
benzimidazole 51; 28 1:2 
4,4'-bipyridine 62; 21 1:1 
imidazole 61; 10 1:1 
benzimidazole 64; 15 1:1 
piperazine 61; 12 1:1 
4,4'-trimethylene 
dipyridine 
65; 30 1:1 
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Figure S1 PXRD results of the grinding experiments with 2. The powder patterns of the products 
either correspond to that of 2 or the co-crystal former. 
 
 
Figure S2 The PXRD results of the mechanochemical experiments between 3 and 4,4'-bipyridine, 
imidazole and benzimidazole. In most cases there appears to be an agreement between the patterns of 
the product and 4,4'-bipyridine, imidazole and benzimidazole. 
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Table S4 Co-crystallisation experiments carried out with 3. All crystallisations were carried out via 
slow evaporation. In most cases no crystals were obtained, and in a few cases crystals of the starting 
materials were obtained. 
Co-former 
Quantity (3; co-
former) /mg 
Mole ratio (3: co-
crystal former) 
Solvent system Product 
4,4'-bipyridine 108; 111 1:3 DCM none 
imidazole 107; 65 1:3 DCM none 
benzimidazole 103; 83 1:3 DCM 
benzimidazole 
hydrate 
m-xylene 100 excess m-xylene none 
benzene 59 As solvent - none 
toluene 60 As solvent - Known 3 
DCM 60 As solvent - none 
chloroform 57 As solvent - none 
acetonitrile 53 As solvent - none 
pyridine 52 As solvent - none 
1,4-dioxane 57 As solvent - none 
NMP 63 As solvent - none 
THF 62 As solvent - none 
DMF 67 As solvent - none 
isophthalic acid 62; 35 1:2 DCM/THF none 
imidazole 69; 15 1:2 DCM/THF none 
benzimidazole 63; 31 1:2 DCM/THF none 
4,4'-bipyridine 63; 33 1:2 DCM/THF none 
 
Table S5 Mechanochemical experiments carried out with 3. Samples were ground by hand in a mortar 
and pestle for approximately 5 minutes, yielding homogenous powders. 
Co-former 
Quantity (3; co-former)  
/mg 
Mole ratio (3: co-
former) 
4,4'-bipyridine 62; 33 1:2 
imidazole 61; 14 1:2 
benzimidazole 60; 13 1:2 
 
 
  
S7 
 
Table S6 Summary of crystallisation experiments with 4 in a range of solvents and with a series of 
potential co-crystal formers. All crystallisations were carried out via slow evaporation. Only one 
crystal of 4 was obtained. 
Co-former 
Quantity (4; co-
former) /mg 
Mole ratio (4: co-
former) 
Solvent system Product 
benzene 58 - - none 
toluene 61 - - none 
DCM 60 - - known 4 
chloroform 58 - - none 
pyridine 60 Excess - none 
acetonitrile 62 - - none 
dioxane 60 - - none 
NMP 59 - - none 
THF 61 - - none 
DMF 60 - - none 
m-xylene 60 - - none 
isophthalic acid 60; 51 1:3 THF none 
imidazole 61; 21 1:3 THF none 
benzimidazole 63; 36 1:3 THF none 
4,4'-bipyridine 62; 48 1:3 THF none 
 
Table S7 Mechanochemical experiments carried out with 4. Samples were ground by hand in a mortar 
and pestle for approximately 5 minutes, yielding homogenous powders. 
Co-former 
Quantity (4; co-
former) /mg 
Mole ratio (4: co-
former) 
4,4'-bipyridine 61; 20 1:1 
imidazole 61; 9 1:1 
benzimidazole 64; 14 1:1 
piperazine 63; 9 1:1 
4,4'-trimethylene 
dipyridine 
63; 28 1:1 
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Figure S3 The PXRD results of mechanochemical experiments with 4. In all cases the product of the 
grinding experiment corresponds to the powder pattern of 4, indicating that no co-crystals were 
formed. 
 
Figure S4 The PXRD results of the precipitate formed when the product of mechanochemical 
synthesis between 2 and benzimidazole is dissolved in THF. 
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Figure S5 The 
31
P NMR spectrum of the precipitate formed when the product of mechanochemical 
synthesis between 2 and benzimidazole is dissolved in THF. Multiple peaks for phosphorous indicates 
that ring cleavage could have occurred. 
Table S8 Summary of crystallisation experiments with 5 from a range of solvents. Approximately 60 
mg of 5 was used in each crystallisation. 
Solvent system Co-crystal former Crystallisation technique Result 
benzene none slow evaporation crystals of 5 
toluene none slow evaporation no crystalline product   
methanol none slow evaporation no crystalline product 
NMP none slow evaporation no crystalline product 
DMSO none slow evaporation no crystalline product 
chloroform none slow evaporation no crystalline product 
acetone none slow evaporation crystals of 5 
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Table S9 Co-crystallisation experiments carried out with 5. 
Co-former Quantity (5; 
co-former) 
/mg 
Mole ratio 
(5: co-
former) 
Solvent 
system 
Crystallisation 
technique 
Product 
pamoic acid 44; 21 1:1 THF slow evaporation none 
piperazine 40; 6 1:1 THF slow evaporation none 
2,6-diaminopyridine 41; 7 1:1 THF slow evaporation, none 
trimesic acid 46; 12 1:1 THF/hexane layering trimesic acid and 
hexane 
isophthalic acid 41; 10 1:1 THF/hexane layering none 
benzonitrile 42; excess - THF slow evaporation none 
2,6-diaminopyridine 40; 12 1:2 THF/diethyl 
ether 
vapour diffusion none 
1,2-diaminoethane 42; 20 1:6 THF/diethyl 
ether 
vapour diffusion none 
1,3-diaminopropane 43; 21 1:6 THF/diethyl 
ether 
vapour diffusion none 
1,4-diaminobutane 42; 15 1:3 THF/diethyl 
ether 
vapour diffusion none none 
1,5-diaminopentane 42; 18 1:3 THF/diethyl 
ether 
vapour diffusion none 
1,6-diaminohexane 41; 15 1:3 THF/diethyl 
ether 
vapour diffusion none 
piperazine 40; 12 1:2 THF/diethyl 
ether 
vapour diffusion none 
p-aminobenzoic acid 40; 15 1:2 DCM/diethyl 
ether 
vapour diffusion  none 
p-aminobenzoic acid 40; 17 1:2 DMF/diethyl 
ether 
vapour diffusion none 
2-aminoterephthalic acid 41; 21 1:2 THF/diethyl 
ether 
vapour diffusion  crystals of 5 
2-aminoterephthalic acid 43; 21 1:2 DMF/diethyl 
ether 
vapour diffusion none 
2,6-dipicolinic acid 42; 21 1:2 THF/DCM vapour diffusion none 
2,6-dipicolinic acid 43; 19 1:2 DMF/ether vapour diffusion crystals of 5 
3,5-dinitrobenzoic acid 40; 30 1:2 THF/diethyl 
ether 
vapour diffusion  3,5-dinitrobenzoic 
acid 
3,5-dinitrobenzoic acid 43; 25 1:2 DMF/diethyl 
ether 
vapour diffusion none 
1,6-
dihydroxynaphthalene 
42; 19 1:2 THF/diethyl 
ether 
vapour diffusion crystals of 5 
1,6-
dihydroxynaphthalene 
45; 19 1:2 DMF/diethyl 
ether 
vapour diffusion crystals of 5 
o-phenylenediamine 48; 15 1:2 THF/diethyl 
ether 
vapour diffusion none 
o-phenylenediamine 40; 16 1:2 DMF/diethyl 
ether 
vapour diffusion none 
phenol 41; 15 1:2 THF/diethyl 
ether 
vapour diffusion crystals of 5 
phenol 40; 11 1:2 DMF/diethyl 
ether 
vapour diffusion crystals of 5 
thiourea 100; 23 1:2 THF Slow evaporation none 
triphenylphosphine oxide 
(TPPO) 
64; 59 1:2 THF Slow evaporation none 
4-hydroxybenzaldehyde 63; 22 1:2 THF Slow evaporation none 
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Table S10 Summary of co-crystallisation experiments with 6. 
Co-crystal former 
Quantity (6; 
co-former) 
/mg 
Mole 
ratio (6: 
co-
former) 
Solvent system 
Crystallisation 
technique 
Product 
iodopentafluorobenzene 52; 41 1:3 DCM Slow evaporation none 
bromopentafluorobenzene 53; 34 1:3 DMSO Slow evaporation 
crystals of 
6 
hexakis(4-iodophenoxy)-
cyclotriphosphazene 
29; 59 1:1 
DMSO/chlorofor
m 
Layered none 
hexakis(4-bromophenoxy)-
cyclotriphosphazene 
36; 54 1:1 
DMSO/chlorofor
m 
Layered 
crystals of 
11 
none 50 - DMSO Slow evaporation 
crystals of 
6 
 
Table S11 Summary of co-crystallisation experiments with 7. The first four crystallisations in the 
table were carried out via slow evaporation, and the rest listed in the table were carried out by layering 
two solutions. 
Co-crystal former 
Mole ratio (7: 
co-former) 
Quantity (7: co-
former) /mg 
Solvent Product 
iodopentafluorobenzene 1:2 52:51 chloroform none 
bromopentafluorobenzene 1:2 51:34 chloroform none 
hexakis(4-iodophenoxy)-
cyclotriphosphazene 
1:1 28:50 chloroform crystals of 12 
hexakis(4-bromophenoxy)-
cyclotriphosphazene 
1:1 31:54 chloroform none 
trimesic acid 1:2 52:32 chloroform/THF none 
terephthalic acid 1:2 51:27 chloroform/DMF co-crystal 7 
fumaric acid 1:3 31:21 THF/DMF none 
pamoic acid 1:3 32:51 THF/DMF none 
boric acid 1:3 33:13 THF/DMF none 
2-aminopyridine 1:3 32:15 THF/DMF none 
urea 1:3 30:12 THF/acetonitrile urea 
adipic acid 1:3 31:14 chloroform/DMF none 
tartaric acid 1:3 30:17 chloroform/DMF none 
maleic acid 1:3 32:10 chloroform/DMF 
Fumaric acid /1,4'-
bipyridin-1-ium-4-
olate co-crystal 
citric acid 1:3 33:17 chloroform/DMF none 
succinic acid 1:3 32:13 chloroform/DMF 
succinic acid/4,4'-
bipyridyl-1-oxide 
co-crystal 
trimesic acid 1:3 33:24 chloroform/DMF none 
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Table S11 (continued) 
Co-crystal former 
Mole ratio (7: 
co-former) 
Quantity (7: co-
former) /mg 
Solvent Product 
malic acid 1:3 31:15 chloroform/DMF none 
pamoic acid 1:3 31:33 chloroform/DMF known SIQCIF 
fumaric acid 1:3 34:12 chloroform/DMF none 
isophthalic acid 1:3 37:16 chloroform/DMF none 
 
Table S12 Summary of crystallisation experiments with 8 in a range of solvents and with a series of 
potential co-crystal formers. 
Co-crystal former 
Quantity (8; 
co-former) 
/mg 
Mole ratio (8: 
co-former) 
Solvent 
system 
Crystallisation 
technique 
Product 
p-aminobenzoic acid 45; 43 1:6 THF slow evaporation none 
2-aminoterephthalic 
acid 
50; 56 1:6 THF slow evaporation none 
3,5-dinitrobenzoic 
acid 
44; 64 1:6 THF slow evaporation 
3,5-dinitrobenzoic 
acid 
phenol 45; 34 1:6 THF slow evaporation none 
o-phenylene diamine 59; 34 1:6 THF slow evaporation none 
2,6-dipicolinic acid 46; 52 1:6 DMF slow evaporation none 
pyridine 46 excess THF slow evaporation none 
4,4'-bipyridine 45; 51 1:6 THF slow evaporation 
4,4-bipyridine 
hydrate 
4,4'-trimethylene 
dipyridine 
42; 64 1:6 THF slow evaporation none 
3,4-lutidine 51; 42 1:6 THF slow evaporation none 
3,5-lutidine 55; 41 1:6 THF slow evaporation none 
2,3-lutidine 48; 45 1:6 THF slow evaporation none 
2,5-lutidine 44; 36 1:6 THF Slow evaporation none 
2,4-lutidine 44; 38 1:6 THF slow evaporation none 
2,6-lutidine 44; 35 1:6 THF Slow evaporation none 
2-picoline 42; 29 1:6 THF slow evaporation none 
3-picoline 49; 28 1:6 THF Slow evaporation none 
4-picoline 43; 31 1:6 THF Slow evaporation none 
3,4-lutidine 54; 47 1:6 
Methanol/ 
hexane 
Layering none 
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Table S12 (continued) 
Co-crystal former 
Quantity (8; 
co-former) 
/mg 
Mole ratio (8: 
co-former) 
Solvent 
system 
Crystallisation 
technique 
Product 
3,5-lutidine 55; 45 1:6 
Methanol/ 
hexane 
Layering none 
2,4-lutidine 54; 45 1:6 
Methanol/ 
hexane 
Layering none 
2,6-lutidine 52; 45 1:6 
Methanol/ 
hexane 
layering none 
3,4-lutidine 50; 44 1:6 DMF Slow evaporation none 
3,5-lutidine 55; excess - DMF Slow evaporation none 
2,3-lutidine 58; excess - - Slow evaporation none 
2,4-lutidine 68; 55 1:6 DMF Slow evaporation none 
2,6-lutidine 53; 41 1:6 DMF Slow evaporation none 
2-picoline neat - - Slow evaporation none 
3-picoline neat - - Slow evaporation none 
4-picoline neat - - Slow evaporation none 
pyridine neat - - Slow evaporation none 
2,6-diaminopyridine 53; 41 1:6 DMF slow evaporation none 
piperazine 71; 50 1:6 THF slow evaporation none 
2,3-lutidine 52; 42 1:6 DMF Slow evaporation none 
2,5-lutidine 58; 46 1:6 DMF Slow evaporation none 
3,5-lutidine 52; 42 1:6 DMF Slow evaporation none 
2-picoline 50; 38 1:6 DMF Slow evaporation none 
3-picoline 54; 34 1:6 DMF Slow evaporation none 
4-picoline 50; 46 1:6 DMF Slow evaporation none 
pyridine 56; 35 1:6 DMF Slow evaporation none 
4,4'-bipyridine 58; 60 1:6 DMF Slow evaporation none 
4,4'-trimethylene 
dipyridine 
50; 90 1:6 DMF Slow evaporation none 
piperazine 57; 39 1:6 DMF Slow evaporation none 
2,6-diaminopyridine 65; 50 1:6 THF Slow evaporation none 
thiourea 101; 58 1:6 THF Slow evaporation none 
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Table S13 Summary of crystallisation experiments with 9 in a range of solvents and with a series of 
potential co-crystal formers. 
Co-former 
Quantity (9; 
co-former) /mg 
Mole ratio (9: 
co-former) 
Solvent system 
Crystallisation 
technique 
Product 
imidazole 100; 25 1:3 THF Inert (under N2) none 
benzimidazole 109; 46 1:3 THF Inert (under N2) none 
4,4'-bipyridine 118; 57 1:3 THF Inert (under N2) none 
2-aminopyridine 106; 35 1:3 THF Inert (under N2) none 
urea 98; 22 1:3 THF/acetonitrile Inert (under N2) none 
pyridine 118; 34 1:3 THF Inert (under N2) none 
3,4-lutidine 118; 40 1:3 THF Inert (under N2) none 
4-picoline 99; 32 1:3 THF Inert (under N2) none 
2,6-
diaminopyridine 
120; 41 1:3 THF Inert (under N2) none 
benzonitrile 161 As solvent - Inert (under N2) none 
2-cyanopyridine 135; 56 1:3 THF Inert (under N2) crystals of 9 
3-cyanopyridine 109; 55 1:3 THF Inert (under N2) none 
4-cyanopyridine 140; 44 1:3 THF Inert (under N2) none 
fluorophenol 50; 37 1:3 Acetonitrile/DCM Slow evaporation none 
1,4-
difluorobenzene 
48; 22 1:3 acetonitrile Slow evaporation none 
1,3-
dibromobenzene 
48; 48 1:3 acetonitrile Slow evaporation none 
4-
bromobenzonitril
e 
54; 35 1:3 Acetonitrile/DCM Slow evaporation crystals of 9 
4-chlorotoluene 51; 28 1:3 acetonitrile Slow evaporation none 
4-iodoaniline 53; 44 1:3 Acetonitrile/DCM Slow evaporation none 
3-bromopyridine 52; 36 1:3 acetonitrile Slow evaporation none 
3-bromoanisol 50; 19 1:1 acetonitrile Slow evaporation none 
-dibromo-p-
xylene 
51; 23 1:1 Acetonitrile/DCM Slow evaporation crystals of 9 
-dibromo-m-
xylene 
52; 21 1:1 Acetonitrile/DCM Slow evaporation none 
-dibromo-o-
xylene 
51; 18 1:1 Acetonitrile/DCM Slow evaporation crystals of 9 
3-
bromobenzotriflu
oride 
52; 20 1:1 acetonitrile Slow evaporation none 
1,2-
dichlorobenzene 
52; 18 1:1 acetonitrile Slow evaporation none 
imidazole 61; 10 1:3 THF Slow evaporation crystals of 9 
benzimidazole 60; 19 1:3 THF Slow evaporation none 
4,4'-bipyridine 60; 23 1:3 THF Slow evaporation none 
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Table S13 (continued) 
Co-former 
Quantity (9; 
co-former) /mg 
Mole ratio (9: 
co-former) 
Solvent system 
Crystallisation 
technique 
Product 
4,4'-trimethylene 
dipyridine 
64; 35 1:3 THF 
Slow 
evaporation 
none 
2-
aminopyrimidine 
61; 17 1:3 THF 
Slow 
evaporation 
none 
pyridine 62; 19 1:3 THF 
Slow 
evaporation 
crystals of 9 
3,4-lutidine 61; 17 1:3 THF 
Slow 
evaporation 
crystals of 9 
4-picoline 61; 16 1:3 THF 
Slow 
evaporation 
crystals of 9 
benzonitrile 62; 18 1:3 THF 
Slow 
evaporation 
none 
2-cyanopyridine 62; 22 1:3 THF 
Slow 
evaporation 
none 
3-cyanopyridine 61; 17 1:3 THF 
Slow 
evaporation 
none 
4-cyanopyridine 65; 20 1:3 THF 
Slow 
evaporation 
none 
cobalt(II)acetate 60; 20 1:1 THF/MeOH Layered crystals of 9 
copper(II)acetate 62; 34 1:1 THF/MeOH Layered crystals of 9 
 
Table S14 Summary of crystallisation experiments with 10 in a range of solvents and with a series of 
potential co-crystal formers. 
Co-former 
Quantity 
(10; co-
former) 
/mg 
Mole ratio 
(10: co-
former) 
Solvent system 
Crystallisation 
technique 
Product 
imidazole 56; 12 1:3 THF Slow evaporation crystals of 10 
benzimidazole 50; 13 1:3 THF Slow evaporation crystals of 10 
-dibromo-p-xylene 51; 30 1:3 THF/DCM Slow evaporation none 
-dibromo-o-xylene 53; 34 1:3 THF/DCM Slow evaporation crystals of 10 
4-bromobenzonitrile 50; 21 1:3 THF/DCM Slow evaporation none 
3,4-lutidine 53; 14 1:3 DCM Slow evaporation none 
pyridine 51; 14 1:3 THF Slow evaporation none 
cobalt(II)acetate 48; 15 1:1 THF/MeOH Layered  none 
copper(II)acetate 54; 12 1:1 THF/MeOH Layered none 
hexakis(4-
fluorophenoxy)cyclo-
triphosphazene 
28; 24 1:1 THF Slow evaporation none 
hexakis(4-
bromophenoxy)cyclo-
triphosphazene 
26; 33 1:1 THF Slow evaporation none 
phosphonitrilic 
chloride trimer 
51; 19 1:1 THF Slow evaporation none 
4-chlorophenol 57; 16 1:3 THF Slow evaporation crystals of 10 
iodopentafluoroben-
zene 
52; 18 1:1 
Chloroform/aceto
-nitrile 
Vapour diffusion 
(AcCN) 
crystals of 10 
bromopentafluoroben-
zene 
50;24 1:1 
Chloroform/aceto
-nitrile 
Vapour diffusion 
(AcCN) 
crystals of 10 
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Table S15 Summary of crystallisation experiments with 11 in a range of solvents and with a series of 
potential co-crystal formers. 
Co-former 
Amount 
(11; co-
former) in 
mg 
Ratio (11: 
co-
former) 
Solvent 
system 
Crystallisation 
technique 
Product 
hexakis(4-
fluorophenoxy)cyclo-
triphosphazene 
63; 41 1:1 THF Slow evaporation crystals of 11 
hexakis(4-iodophenoxy)-
cyclotriphosphazene 
65; 78 1:1 THF Slow evaporation none 
imidazole 62; 10 1:3 THF Slow evaporation crystals of 11 
-dibromo-p-xylene 63; 30 1:3 THF/DCM Slow evaporation 
-dibromo-p-
xylene 
-dibromo-o-xylene 64; 36 1:3 THF/DCM Slow evaporation none 
4-bromobenzonitrile 63; 29 1:3 THF/DCM Slow evaporation crystals of 11 
cobalt(II)acetate 60; 18 1:2 THF/MeOH Layered  crystals of 11 
copper(II)acetate 60; 12 1:2 THF/MeOH Layered  crystals of 11 
3,4-lutidine 61; 14 1:3 THF Slow evaporation crystals of 11 
pyridine 62; 17 1:3 THF Slow evaporation crystals of 11 
5 68; 39 1:1 THF Slow evaporation crystals of 11 
phosphonitrilic chloride 
trimer 
65; 18 1:1 THF Slow evaporation crystals of 11 
bromopentafluoroben-
zene 
54; 18 1:1 
Chloroform/
acetonitrile 
Vapour diffusion 
(AcCN) 
crystals of 11 
iodopentafluorobenzene  52; 14 1:1 
Chloroform/
acetonitrile 
Vapour diffusion 
(AcCN) 
crystals of 11 
bromopentafluorobenzene 51; 52 1:4 
Chloroform/
acetonitrile 
Vapour diffusion 
(AcCN) 
crystals of 11 
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Table S16 Summary of crystallisation experiments with 12 in a range of solvents and with a series of 
potential co-crystal formers. 
Co-former 
Quantity 
(12; co-
former) 
/mg 
Mole ratio 
(12: co-
former) 
Solvent 
system*
 
Crystallisation 
technique 
Product 
4-iodoaniline 61; 32 1:3 DCM 
Slow 
evaporation 
crystals of 12 
acetonitrile 59 excess 
DCM/ 
acetonitrile
 
Slow 
evaporation 
none 
4-bromobenzonitrile 62; 26 1:3 DCM
 Slow 
evaporation 
crystals of 12 
1,3-dicyanobenzene 62; 19 1:3 DCM
 Slow 
evaporation 
crystals of 12 
2-cyanopyridine 59; 16 1:3 DCM 
Slow 
evaporation 
none 
3-cyanopyridine 61; 16 1:3 DCM 
Slow 
evaporation 
none 
4-cyanopyridine 65; 22 1:3 DCM 
Slow 
evaporation 
crystals of 12 
4-iodobenzonitrile 64; 31 1:3 DCM 
Slow 
evaporation 
none 
benzonitrile 63; 16 1:3 DCM 
Slow 
evaporation 
crystals of 12 
nitrobenzene 66; 26 1:3 DCM 
Slow 
evaporation 
none 
o-tolunitrile 65; 21 1:3 DCM 
Slow 
evaporation 
none 
m-tolunitrile 61; 22 1:3 DCM 
Slow 
evaporation 
none 
p-tolunitrile 61; 19 1:3 DCM 
Slow 
evaporation 
none 
iodophenol 60; 32 1:3 DCM/THF 
Slow 
evaporation 
crystals of 12 
1,2-bis(2-pyridyl)ethylene 65; 25 1:3 DCM/THF 
Slow 
evaporation 
crystals of 12 
4,4’-diiodobiphenyl 67; 51 1:3 DCM 
Slow 
evaporation 
none 
1,4-diiodobenzene 64; 46 1:3 DCM 
Slow 
evaporation 
none 
2-iodopropane 62; 24 1:3 DCM 
Slow 
evaporation 
none 
propionitrile 64; 13 1:3 DCM 
Slow 
evaporation 
none 
terephthalonitrile 64; 19 1:3 
DCM/ 
acetonitrile 
Slow 
evaporation 
crystals of 12 
4-(4-
fluorophenyl)benzonitrile 
62; 26 1:3 DCM 
Slow 
evaporation 
none 
hexakis(4-
fluorophenoxy)cyclotri-
phosphazene 
66; 38 1:1 Chloroform 
Slow 
evaporation 
crystals of 12 
and 9 
iodopentafluorobenzene 51; 11 1:1 
Chloroform/ 
acetonitrile 
Vapour diffusion 
(AcCN) 
crystals of 12 
iodopentafluorobenzene 51; 50 1:4 
Chloroform/ 
acetonitrile 
Vapour diffusion 
(AcCN) 
crystals of 12 
bromopentafluorobenzene 50; 24 1:1 
Chloroform/ 
acetonitrile 
Vapour diffusion 
(AcCN) 
crystals of 12 
*
These crystallisations were also repeated in chloroform
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Table S17 Crystallisations from the melt with 9, 10, 11 and 12 in a 1:1 mole ratio 
Compound 1 Compound 2 
Amount (cmp 1; 
cmp 2) /mg 
Method 
hexakis(4-fluorophenoxy)-
cyclotriphosphazene 
hexakis(4-chlorophenoxy)-
cyclotriphosphazene 
46; 52 Ground together & melted 
hexakis(4-fluorophenoxy)-
cyclotriphosphazene 
hexakis(4-bromophenoxy)-
cyclotriphosphazene 
45; 68 Ground together & melted 
hexakis(4-fluorophenoxy)-
cyclotriphosphazene 
hexakis(4-iodophenoxy)-
cyclotriphosphazene 
42; 82 Ground together & melted 
hexakis(4-chlorophenoxy)-
cyclotriphosphazene 
hexakis(4-bromophenoxy)-
cyclotriphosphazene 
39; 53 Ground together & melted 
hexakis(4-chlorophenoxy)-
cyclotriphosphazene 
hexakis(4-iodophenoxy)-
cyclotriphosphazene 
41; 66 Ground together & melted 
hexakis(4-iodophenoxy)-
cyclotriphosphazene 
hexakis(4-bromophenoxy)-
cyclotriphosphazen 
51; 41 Ground together & melted 
 
 
Figure S6 DSC analysis of the monoclinic form of hexakis(4-fluorophenoxy)cyclotriphosphazene (9), 
with a melt at 128.4 °C and a recrystallization event upon cooling at 53.6 °C. This structure undergoes 
single-crystal to single-crystal polymorphic transitions where 9 (the monoclinic P form) converts to 
9 between 115 and 125 °C before melting. 
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Figure S7 DSC analysis of the triclinic form of hexakis(4-fluorphenoxy)cyclotriphosphazene (9). The 
triclinic form (9) converts to 9 around 100 °C before the melt at 129.5 °C. 
 
 
Figure S8 DSC analysis of hexakis(4-chlorophenyl)cyclotriphosphazene (10), with a melt occurring at 
152.0 °C. 
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Figure S9 DSC analysis of hexakis(4-bromophenyl)cyclotriphosphazene (11), with a melt occurring at 
174.5 °C and a recrystallization event upon cooling at 92.1 °C. 
 
 
Figure S10 DSC analysis of hexakis(4-iodophenyl)cyclotriphosphazene (12), with a melt at 185.9 °C. 
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Figure S11 DSC analysis of the melt product (9/10) of the fluoro and chloro derivatives. Melting 
occurs before the melting point of the fluorophenoxy derivative (129 °C). 
 
 
Figure S12 DSC analysis of the product of 11 and 12. The melting point of 11/12 is lower than that of 
both the reagents. 
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Synthesis of 1-12 
All chemicals were purchased from Sigma-Aldrich and used without further purification. THF, 
diethylether and toluene were distilled over sodium sand or wire with benzophenone as indicator, 
under an atmosphere of dry nitrogen. DCM and acetonitrile were distilled over dried calcium hydride 
under an atmosphere of dry nitrogen. Acetone and n-hexane were distilled over dried calcium chloride 
under nitrogen. 
1
H and 
31
P NMR spectra were obtained using a 300 MHz Varian VNMRS or a 400 MHz Varian Unity 
Inova. Chemical shift values are in ppm and were referenced to either chloroform-d or DMSO-d6. Data 
for 
1
H spectra are reported as chemical shift (δ ppm) (integration, multiplicity, coupling constant 
(Hz)). H3PO4 was used as an external standard for 
31
P NMR. 
All reactions were performed under an atmosphere of dry nitrogen unless otherwise stated. 
 
Tris(1,3-diaminopropane)cyclotriphosphazene (1)
1
  
N3P3Cl6 (0.5 g,1.44 mmol) was dissolved in 50 ml of a 7:3 mixture of n-hexane:DCM. To this 
mixture, 0.8 ml (8.64 mmol) 1,3-diaminopropane was added. The reaction mixture was refluxed for 4 
hours, after which the solution was cooled and filtered and the solvent removed under reduced 
pressure. The resultant white powder was further purified by recrystallisation from methanol. Yield: 
62% (0.313 g, 0.89 mmol). 
1
H NMR (DMSO-d6, 400 MHz): δ ppm 1.53 (2H, m), 3.04 (4H, m), 3.48 (2H, s), 
31
P NMR (DMSO-d6, 
400 MHz, H3PO4): δ ppm 13.86 (d), 20.45 (t). 
Crystals of 1 were also grown from a THF/hexane solution. This proved to be the known hydrate.
1a
  
 
4,4,6,6-Tetrachloro-2,2-(biphenyl-2,2'-dioxy)cyclotriphosphazene (2)
2
 
A mixture of N3P3Cl6 (1.018 g, 2.88 mmol), 2,2'-biphenol (0.543 g, 2.88 mmol) and K2CO3 (2.013 g, 
14.4 mmol) were stirred together in 40 ml acetone at room temperature for 30 minutes. The volatiles 
were evaporated in vacuo and the residue extracted with 4 x 15 ml DCM. The solvent was evaporated 
to give a white solid, which was recrystallised from DCM/petroleum ether. Yield: 80% (1.071 g, 2.32 
mmol). Mp.: 181 – 189 °C. 
1
H NMR (CDCl3, 400 MHz): δ ppm 7.57 (2H, d, J = 7.62 Hz), 7.49 (2H, t, J = 7.42 Hz), 7.41 (2H, t, J 
= 7.62 Hz), 7.33 (2H, d, 8.01 Hz), 
31
P NMR (CDCl3, 400 MHz, H3PO4): δ ppm 21.87 (d, Cl2), 9.74 (t, 
C12O2H8). 
 
2,2-Dichloro-4,4,6,6-bis[spiro(2',2''-dioxy-1',1''-biphenylyl]cyclotriphosphazene (3)
3
 
N3P3Cl6 (2 g, 5.75 mmol), biphenyl-2,2'-diol (2.14 g, 11.51 mmol) and  K2CO3 (3.98 g, 28.77 mmol) 
were mixed in 20 ml acetone at 0 °C. The reaction mixture was stirred at room temperature for 24 
hours, and then the solvent was removed in vacuo. The product was extracted by washing with 15 ml 
of DCM four times, filtering each time with a cannula filter. The solvent was then removed under 
vacuum, yielding a white powder. Yield: 86% (2.847 g, 4.96 mmol). Mp.: 268 – 275 °C. 
1
H NMR (CDCl3, 300 MHz): δ ppm 7.55 (4H, d, J = 7.63 Hz), 7.46 (4H, d, J = 7.63 Hz), 7.36 (8H, m), 
31
P NMR (CDCl3, 300 MHz, H3PO4): δ ppm 19.79 (d, C12O2H8), 29.19 (dd, Cl2). 
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Tris(2,2'-dioxybiphenyl)cyclotriphosphazene (4)
4
 
N3P3Cl6 (1.003 g, 2.88 mmol), 2,2'-biphenol (1.815 g, 9.66 mmol) and  K2CO3 (3.010 g, 21.8 mmol) 
were refluxed for 7 hours in 140 ml acetone. The solvent was evaporated in vacuo and the residue 
washed with 100 ml water, 100 ml aqueous NaOH (0.5 M), 2 x 50 ml water, 50 ml ethanol and 50 ml 
ether. The white product was dried under vacuum. Yield: 75% (1.278 g, 1.86 mmol). Mp.: >350 °C. 
1
H NMR (CDCl3, 400 MHz): δ ppm 7.52 (2H, d, J = 7.62 Hz), 7.41 (4H, m), 7.33 (2H, t, J = 7.642 
Hz), 
31
P NMR (CDCl3, 400 MHz, H3PO4): δ ppm 26.27 (s). 
2,2-Bis(4-formylphenoxy)-4,4,6,6-bis[spiro(2',2''-dioxy-1',1''-biphenylyl]cyclotriphosphazene (5)
3
 
Compound 3 (2 g, 3.48 mmol), 4-hydroxybenzaldehyde (0.854 g, 6.96 mmol) and K2CO3 (2.663 g, 
19.28 mmol) were added to 20 ml THF at 0 °C. The mixture was refluxed for 5 hours and the solvent 
removed under vacuum. The resulting solid was extracted with DCM (4 x 10 ml), and the solvent 
subsequently removed under vacuum. The product was recrystallised from acetone. Yield: 72% 
(1.881 g, 2.52 mmol). Mp.: 220 – 224 °C 
1
H NMR (CDCl3, 300 MHz): δ ppm 7.07 (2H, d, J = 7.80 Hz), 7.31 – 7.41 (4H, m), 7.54 (4H, t, J = 
8.58 Hz), 7.96 (2H, d, 8.19 Hz), 10.01 (1H, s) 
31
P NMR (CDCl3, 300 MHz, H3PO4): δ ppm 9.62 – 
11.69 (tt), 25.59 – 26.71 (dt). 
 
Hexakis(4-cyanophenoxy)cyclotriphosphazene (6)
5
 
A mixture of 4-cyanophenol (2.071 g, 17.28 mmol) and  K2CO3 (4.804 g, 34.56 mmol) was prepared 
in 80 ml THF. N3P3Cl6 (1.030 g, 2.88 mmol) in 15 ml THF was added dropwise to this mixture. The 
reaction mixture was refluxed for 6 hours with vigorous stirring. The solvent was removed in vacuo 
and the residue dispersed in 100 ml water. The resultant white solid was separated by filtration and 
allowed to dry. Yield: 94 % (2.284 g, 2.707 mmol). Mp.: 263 – 265 °C. 
1
H NMR (DMSO-d6, 400 MHz): δ ppm 7.16 (2H, d, 8.79 Hz), 7.82 (2H, d, 8.79 Hz), 
31
P NMR 
(DMSO-d6, 400 MHz, H3PO4): δ ppm 8.51 (s). 
 
Hexakis(4-pyridyloxy)cyclotriphosphazene (7)
6
 
4-hydroxypyridine (0.826 g, 8.64 mmol) and K2CO3 (1.818 g, 12.96 mmol) were added to 50 ml THF. 
N3P3Cl6 (0.503 g, 1.44 mmol) was added to this mixture, which was then stirred for two and a half 
days at room temperature, after which it was refluxed for approximately 6 hours. The solvent was 
removed under vacuum and the residue washed with 100 ml water. The product was isolated by 
filtration and dried in vacuo to yield a light yellow product. Yield: 89% (0.897 g, 1.28 mmol). Mp.: 
163 – 165 °C. 
1
H NMR (CDCl3, 400 MHz): δ ppm 6.93 (2H, d, 6.44 Hz), 8.50 (2H, d, 6.25 Hz), 
31
P NMR (CDCl3, 
400 MHz, H3PO4): δ ppm 7.30 (s). 
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Hexakis(4-hydroxyphenoxy)cyclotriphosphazene (8)
7
 
Hexakis(4-methoxyphenoxy)cyclotriphosphazene 
A suspension of sodium 4-methoxyphenoxide was prepared in 20 ml dry THF by allowing 4-
methoxyphenol (4.274 g, 34.5 mmol) to react with NaH (1.385 g as a 60 % dispersion in mineral oil; 
equivalent to 0.828 g, 34.5 mmol pure NaH). The NaH was washed with dry petroleum ether to 
remove the mineral oil prior to use. A solution of N3P3Cl6 (2 g, 5.75 mmol) in 20 ml THF was added 
dropwise to this suspension. On complete addition of the phosphonitrilic chloride trimer, the reaction 
mixture was refluxed for 24 hours with stirring. The reaction mixture was cooled and washed with 100 
ml water in order to precipitate the product as a white powder. Yield: 82% (4.136 g, 4.733 mmol). 
Mp.: 105 – 106 °C 
1
H NMR (CDCl3, 400 MHz): δ ppm 3.72 (3H, s), 6.77 (4H, s) 
Hexakis(4-hydroxyphenoxy)cyclotriphosphazene (8) 
Hexakis(4-methoxyphenoxy)-cyclotriphosphazene (3 g, 3.43 mmol) was dissolved in 30 ml DCM. A 
solution of BBr3 (2 ml, 20.6 mmol) in 30 ml DCM was added dropwise to the solution of 
cyclotriphosphazene. The solution was allowed to stir for 3 hours, after which it was poured carefully 
into 100 ml of water to precipitate the product. The white precipitate was filtered off, washed with 
water and dried. Yield: 85% (2.303 g, 2.92 mmol). 
1
H NMR (DMSO-d6, 400 MHz): δ ppm 6.59 (2H, s), 6.61 (2H, s), 
31
P NMR (DMSO-d6, 400 MHz, 
H3PO4): δ ppm 22.32 (s). 
 
Hexakis(4-fluorophenyl)cyclotriphosphazene (9)
8,9 
This synthetic procedure was not performed under inert conditions. 
4-fluorophenol (1.94 g, 17.28 mmol) and N3P3Cl6 (0.998 g, 2.88 mmol) were dissolved in 60 ml 
acetone. K2CO3 (4.797 g, 120.96 mmol) was added to this mixture, and the reaction mixture was 
refluxed for 12 hours. The precipitate was filtered off, washed with DCM and combined with the 
filtrate. The solvent was then removed in vacuo. The white powder thus obtained was recrystallised 
from methanol. Yield: 65% (3.131 g, 3.91 mmol). Mp. 129 °C 
1
H NMR (CDCl3, 400 MHz): δ ppm 6.88 (2H, s), 6.9 (2H, s), 
31
P NMR (CDCl3, 400 MHz, H3PO4): δ 
ppm 9.86 (s). 
 
Hexakis(4-chlorophenyl)cyclotriphosphazene (10)
8
 
4-chlorophenol (2.240 g, 17.28 mmol) and K2CO3 (4.793 g, 34.56 mmol) were stirred together in 50 
ml acetone. N3P3Cl6 (1.004 g, 2.88 mmol) dissolved in 10 ml acetone was added to the mixture, which 
was then refluxed for 1 day. The solvent was removed under vacuum and the product extracted with 
DCM. The product was further purified by recrystallisation from acetonitrile. Yield: 76 % (1.982 g, 
2.2 mmol). Mp. 152 °C  
1
H NMR (CDCl3, 400 MHz): δ ppm 6.68 (2H, d, 8.20 Hz), 7.17 (2H, d, 8.40 Hz), 
31
P NMR (CDCl3, 
400 MHz, H3PO4): δ ppm 9.59 (s). 
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Hexakis(4-bromophenyl)cyclotriphosphazene (11)
8
 
4-bromophenol (3.030 g, 17.28 mmol) and K2CO3 (4.779 g, 34.56 mmol) were added to 50 ml 
acetone. N3P3Cl6 (1.011 g, 2.88 mmol) in 10 ml acetone was added to the mixture, which was then 
refluxed for 2 days. The solvent was removed under vacuum and the product purified by 
recrystallisation from acetonitrile. Yield: 79 % (2.684 g, 2.3 mmol). Mp. 176.8 °C. 
1
H NMR (CDCl3, 400 MHz): δ ppm 6.75 (2H, d, 8.79 Hz), 7.33 (2H, d, 8.89 Hz), 
31
P NMR (CDCl3, 
400 MHz, H3PO4): δ ppm 9.29 (s). 
 
Hexakis(4-iodophenyl)cyclotriphosphazene (12)
8
 
4-iodophenol (3.844 g, 17.28 mmol) and N3P3Cl6 (1.007 g, 2.88 mmol) were dissolved in 75 ml 
acetone. K2CO3 (4.821 g, 34.56 mmol) was added to this mixture, which was refluxed for 2 days. The 
solvent was evaporated under vacuum and the product was extracted with 3 x 20 ml DCM. The 
product was further purified by recrystallisation from acetonitrile. Yield: 65% (2.702 g, 1.86 mmol). 
Mp. 187.6 °C. 
1
H NMR (CDCl3, 400 MHz): δ ppm 6.62 (2H, d, J = 8.79 Hz), 7.52 (2H, d, 8.79 Hz), 
31
P NMR 
(CDCl3, 400 MHz, H3PO4): δ ppm 9.27 (s). 
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Scheme S1 The cyclotriphosphazenes investigated in this work. 
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Co-crystallisation experiments 
The components of each crystallisation experiment (see Tables S1, S2, S4, S6, S8-14) were dissolved 
in the appropriate solvent with gentle heat and stirring. In cases where there were still undissolved 
particles, the solution was filtered through a non-sterile 33 mm Millex-HV syringe filter unit into a 
glass vial. All solutions were left to stand at room temperature and crystals were formed either via 
slow evaporation of the solvent, vapour diffusion of one solvent into another or solutions were layered 
with a second solvent to induce crystal formation at the interface of the two solutions. 
 
Table S1 Co-crystallisation experiments carried out with 1. All crystallisations were carried out via 
slow evaporation. Crystals obtained were that of the known hydrate of 1 (CSD-COPVAE) or no 
product was obtained. 
Co-former 
Quantity (1; co-
former) /mg 
Mole ratio  
(1:co-former) 
Solvent system Product 
isophthalic acid 29; 14 1:1 methanol none 
terephthalic acid 15; 15 1:2 methanol terephthalic acid 
trimesic acid 29; 20 1:1 methanol none 
succinic acid 14; 15 1:3 methanol none 
maleic acid 13; 13 1:3 methanol/THF none 
tartaric acid 13; 12 1:3 methanol none 
2,6-naphthalene 
dicarboxylic acid 
29:18 1:1 methanol 
2,6-naphthalene 
dicarboxylic acid 
solvent - - THF none 
solvent - - hexane/THF known COPVAE 
solvent - - DCM none 
solvent - - DMSO none 
solvent - - acetonitrile known COPVAE 
solvent - - methanol none 
solvent - - ethanol none 
solvent - - DMF none 
solvent - - NMP none 
solvent - - chloroform none 
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Table S2 Co-crystallisation experiments carried out with 2. All crystallisations were carried out via 
slow evaporation. In some cases crystals of the starting materials were obtained, otherwise no crystals 
were obtained. 
Co-former 
Quantity (2; co-
former) /mg 
Mole ratio (2:co-
former) 
Solvent system Product 
DCM 50 As solvent - none 
benzene 45 As solvent - none 
toluene 46 As solvent - none 
chloroform 54 As solvent - none 
acetonitrile 49 As solvent - none 
pyridine 48 As solvent - none 
1,4-dioxane 55 As solvent - none 
NMP 51 As solvent - none 
THF 74 As solvent - none 
DMF 68 As solvent - none 
isophthalic acid 53; 41 1:2 DCM/THF none 
imidazole 55; 25 1:3 DCM/THF none 
benzimidazole 59; 33 1:3 DCM/THF 
benzimidazole 
hydrate 
4,4'-bipyridine 52; 35 1:2 DCM/THF none 
benzonitrile 54 As solvent - none 
3,4-lutidine 62; 35 1:3 DCM none 
 
Table S3 Mechanochemical experiments carried out with 2. Samples were ground by hand in a mortar 
and pestle for approximately 5 minutes, yielding homogenous powders. 
Co-former 
Quantity (2; co-former) 
/mg 
Mole ratio (2: co-
former) 
4,4'-bipyridine 28; 32 1:2 
imidazole 56; 24 1:2 
benzimidazole 51; 28 1:2 
4,4'-bipyridine 62; 21 1:1 
imidazole 61; 10 1:1 
benzimidazole 64; 15 1:1 
piperazine 61; 12 1:1 
4,4'-trimethylene 
dipyridine 
65; 30 1:1 
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Figure S1 PXRD results of the grinding experiments with 2. The powder patterns of the products 
either correspond to that of 2 or the co-crystal former. 
 
 
Figure S2 The PXRD results of the mechanochemical experiments between 3 and 4,4'-bipyridine, 
imidazole and benzimidazole. In most cases there appears to be an agreement between the patterns of 
the product and 4,4'-bipyridine, imidazole and benzimidazole. 
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Table S4 Co-crystallisation experiments carried out with 3. All crystallisations were carried out via 
slow evaporation. In most cases no crystals were obtained, and in a few cases crystals of the starting 
materials were obtained. 
Co-former 
Quantity (3; co-
former) /mg 
Mole ratio (3: co-
crystal former) 
Solvent system Product 
4,4'-bipyridine 108; 111 1:3 DCM none 
imidazole 107; 65 1:3 DCM none 
benzimidazole 103; 83 1:3 DCM 
benzimidazole 
hydrate 
m-xylene 100 excess m-xylene none 
benzene 59 As solvent - none 
toluene 60 As solvent - Known 3 
DCM 60 As solvent - none 
chloroform 57 As solvent - none 
acetonitrile 53 As solvent - none 
pyridine 52 As solvent - none 
1,4-dioxane 57 As solvent - none 
NMP 63 As solvent - none 
THF 62 As solvent - none 
DMF 67 As solvent - none 
isophthalic acid 62; 35 1:2 DCM/THF none 
imidazole 69; 15 1:2 DCM/THF none 
benzimidazole 63; 31 1:2 DCM/THF none 
4,4'-bipyridine 63; 33 1:2 DCM/THF none 
 
Table S5 Mechanochemical experiments carried out with 3. Samples were ground by hand in a mortar 
and pestle for approximately 5 minutes, yielding homogenous powders. 
Co-former 
Quantity (3; co-former)  
/mg 
Mole ratio (3: co-
former) 
4,4'-bipyridine 62; 33 1:2 
imidazole 61; 14 1:2 
benzimidazole 60; 13 1:2 
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Table S6 Summary of crystallisation experiments with 4 in a range of solvents and with a series of 
potential co-crystal formers. All crystallisations were carried out via slow evaporation. Only one 
crystal of 4 was obtained. 
Co-former 
Quantity (4; co-
former) /mg 
Mole ratio (4: co-
former) 
Solvent system Product 
benzene 58 - - none 
toluene 61 - - none 
DCM 60 - - known 4 
chloroform 58 - - none 
pyridine 60 Excess - none 
acetonitrile 62 - - none 
dioxane 60 - - none 
NMP 59 - - none 
THF 61 - - none 
DMF 60 - - none 
m-xylene 60 - - none 
isophthalic acid 60; 51 1:3 THF none 
imidazole 61; 21 1:3 THF none 
benzimidazole 63; 36 1:3 THF none 
4,4'-bipyridine 62; 48 1:3 THF none 
 
Table S7 Mechanochemical experiments carried out with 4. Samples were ground by hand in a mortar 
and pestle for approximately 5 minutes, yielding homogenous powders. 
Co-former 
Quantity (4; co-
former) /mg 
Mole ratio (4: co-
former) 
4,4'-bipyridine 61; 20 1:1 
imidazole 61; 9 1:1 
benzimidazole 64; 14 1:1 
piperazine 63; 9 1:1 
4,4'-trimethylene 
dipyridine 
63; 28 1:1 
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Figure S3 The PXRD results of mechanochemical experiments with 4. In all cases the product of the 
grinding experiment corresponds to the powder pattern of 4, indicating that no co-crystals were 
formed. 
 
Figure S4 The PXRD results of the precipitate formed when the product of mechanochemical 
synthesis between 2 and benzimidazole is dissolved in THF. 
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Figure S5 The 
31
P NMR spectrum of the precipitate formed when the product of mechanochemical 
synthesis between 2 and benzimidazole is dissolved in THF. Multiple peaks for phosphorous indicates 
that ring cleavage could have occurred. 
Table S8 Summary of crystallisation experiments with 5 from a range of solvents. Approximately 60 
mg of 5 was used in each crystallisation. 
Solvent system Co-crystal former Crystallisation technique Result 
benzene none slow evaporation crystals of 5 
toluene none slow evaporation no crystalline product   
methanol none slow evaporation no crystalline product 
NMP none slow evaporation no crystalline product 
DMSO none slow evaporation no crystalline product 
chloroform none slow evaporation no crystalline product 
acetone none slow evaporation crystals of 5 
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Table S9 Co-crystallisation experiments carried out with 5. 
Co-former Quantity (5; 
co-former) 
/mg 
Mole ratio 
(5: co-
former) 
Solvent 
system 
Crystallisation 
technique 
Product 
pamoic acid 44; 21 1:1 THF slow evaporation none 
piperazine 40; 6 1:1 THF slow evaporation none 
2,6-diaminopyridine 41; 7 1:1 THF slow evaporation, none 
trimesic acid 46; 12 1:1 THF/hexane layering trimesic acid and 
hexane 
isophthalic acid 41; 10 1:1 THF/hexane layering none 
benzonitrile 42; excess - THF slow evaporation none 
2,6-diaminopyridine 40; 12 1:2 THF/diethyl 
ether 
vapour diffusion none 
1,2-diaminoethane 42; 20 1:6 THF/diethyl 
ether 
vapour diffusion none 
1,3-diaminopropane 43; 21 1:6 THF/diethyl 
ether 
vapour diffusion none 
1,4-diaminobutane 42; 15 1:3 THF/diethyl 
ether 
vapour diffusion none none 
1,5-diaminopentane 42; 18 1:3 THF/diethyl 
ether 
vapour diffusion none 
1,6-diaminohexane 41; 15 1:3 THF/diethyl 
ether 
vapour diffusion none 
piperazine 40; 12 1:2 THF/diethyl 
ether 
vapour diffusion none 
p-aminobenzoic acid 40; 15 1:2 DCM/diethyl 
ether 
vapour diffusion  none 
p-aminobenzoic acid 40; 17 1:2 DMF/diethyl 
ether 
vapour diffusion none 
2-aminoterephthalic acid 41; 21 1:2 THF/diethyl 
ether 
vapour diffusion  crystals of 5 
2-aminoterephthalic acid 43; 21 1:2 DMF/diethyl 
ether 
vapour diffusion none 
2,6-dipicolinic acid 42; 21 1:2 THF/DCM vapour diffusion none 
2,6-dipicolinic acid 43; 19 1:2 DMF/ether vapour diffusion crystals of 5 
3,5-dinitrobenzoic acid 40; 30 1:2 THF/diethyl 
ether 
vapour diffusion  3,5-dinitrobenzoic 
acid 
3,5-dinitrobenzoic acid 43; 25 1:2 DMF/diethyl 
ether 
vapour diffusion none 
1,6-
dihydroxynaphthalene 
42; 19 1:2 THF/diethyl 
ether 
vapour diffusion crystals of 5 
1,6-
dihydroxynaphthalene 
45; 19 1:2 DMF/diethyl 
ether 
vapour diffusion crystals of 5 
o-phenylenediamine 48; 15 1:2 THF/diethyl 
ether 
vapour diffusion none 
o-phenylenediamine 40; 16 1:2 DMF/diethyl 
ether 
vapour diffusion none 
phenol 41; 15 1:2 THF/diethyl 
ether 
vapour diffusion crystals of 5 
phenol 40; 11 1:2 DMF/diethyl 
ether 
vapour diffusion crystals of 5 
thiourea 100; 23 1:2 THF Slow evaporation none 
triphenylphosphine oxide 
(TPPO) 
64; 59 1:2 THF Slow evaporation none 
4-hydroxybenzaldehyde 63; 22 1:2 THF Slow evaporation none 
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Table S10 Summary of co-crystallisation experiments with 6. 
Co-crystal former 
Quantity (6; 
co-former) 
/mg 
Mole 
ratio (6: 
co-
former) 
Solvent system 
Crystallisation 
technique 
Product 
iodopentafluorobenzene 52; 41 1:3 DCM Slow evaporation none 
bromopentafluorobenzene 53; 34 1:3 DMSO Slow evaporation 
crystals of 
6 
hexakis(4-iodophenoxy)-
cyclotriphosphazene 
29; 59 1:1 
DMSO/chlorofor
m 
Layered none 
hexakis(4-bromophenoxy)-
cyclotriphosphazene 
36; 54 1:1 
DMSO/chlorofor
m 
Layered 
crystals of 
11 
none 50 - DMSO Slow evaporation 
crystals of 
6 
 
Table S11 Summary of co-crystallisation experiments with 7. The first four crystallisations in the 
table were carried out via slow evaporation, and the rest listed in the table were carried out by layering 
two solutions. 
Co-crystal former 
Mole ratio (7: 
co-former) 
Quantity (7: co-
former) /mg 
Solvent Product 
iodopentafluorobenzene 1:2 52:51 chloroform none 
bromopentafluorobenzene 1:2 51:34 chloroform none 
hexakis(4-iodophenoxy)-
cyclotriphosphazene 
1:1 28:50 chloroform crystals of 12 
hexakis(4-bromophenoxy)-
cyclotriphosphazene 
1:1 31:54 chloroform none 
trimesic acid 1:2 52:32 chloroform/THF none 
terephthalic acid 1:2 51:27 chloroform/DMF co-crystal 7 
fumaric acid 1:3 31:21 THF/DMF none 
pamoic acid 1:3 32:51 THF/DMF none 
boric acid 1:3 33:13 THF/DMF none 
2-aminopyridine 1:3 32:15 THF/DMF none 
urea 1:3 30:12 THF/acetonitrile urea 
adipic acid 1:3 31:14 chloroform/DMF none 
tartaric acid 1:3 30:17 chloroform/DMF none 
maleic acid 1:3 32:10 chloroform/DMF 
Fumaric acid /1,4'-
bipyridin-1-ium-4-
olate co-crystal 
citric acid 1:3 33:17 chloroform/DMF none 
succinic acid 1:3 32:13 chloroform/DMF 
succinic acid/4,4'-
bipyridyl-1-oxide 
co-crystal 
trimesic acid 1:3 33:24 chloroform/DMF none 
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Table S11 (continued) 
Co-crystal former 
Mole ratio (7: 
co-former) 
Quantity (7: co-
former) /mg 
Solvent Product 
malic acid 1:3 31:15 chloroform/DMF none 
pamoic acid 1:3 31:33 chloroform/DMF known SIQCIF 
fumaric acid 1:3 34:12 chloroform/DMF none 
isophthalic acid 1:3 37:16 chloroform/DMF none 
 
Table S12 Summary of crystallisation experiments with 8 in a range of solvents and with a series of 
potential co-crystal formers. 
Co-crystal former 
Quantity (8; 
co-former) 
/mg 
Mole ratio (8: 
co-former) 
Solvent 
system 
Crystallisation 
technique 
Product 
p-aminobenzoic acid 45; 43 1:6 THF slow evaporation none 
2-aminoterephthalic 
acid 
50; 56 1:6 THF slow evaporation none 
3,5-dinitrobenzoic 
acid 
44; 64 1:6 THF slow evaporation 
3,5-dinitrobenzoic 
acid 
phenol 45; 34 1:6 THF slow evaporation none 
o-phenylene diamine 59; 34 1:6 THF slow evaporation none 
2,6-dipicolinic acid 46; 52 1:6 DMF slow evaporation none 
pyridine 46 excess THF slow evaporation none 
4,4'-bipyridine 45; 51 1:6 THF slow evaporation 
4,4-bipyridine 
hydrate 
4,4'-trimethylene 
dipyridine 
42; 64 1:6 THF slow evaporation none 
3,4-lutidine 51; 42 1:6 THF slow evaporation none 
3,5-lutidine 55; 41 1:6 THF slow evaporation none 
2,3-lutidine 48; 45 1:6 THF slow evaporation none 
2,5-lutidine 44; 36 1:6 THF Slow evaporation none 
2,4-lutidine 44; 38 1:6 THF slow evaporation none 
2,6-lutidine 44; 35 1:6 THF Slow evaporation none 
2-picoline 42; 29 1:6 THF slow evaporation none 
3-picoline 49; 28 1:6 THF Slow evaporation none 
4-picoline 43; 31 1:6 THF Slow evaporation none 
3,4-lutidine 54; 47 1:6 
Methanol/ 
hexane 
Layering none 
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Table S12 (continued) 
Co-crystal former 
Quantity (8; 
co-former) 
/mg 
Mole ratio (8: 
co-former) 
Solvent 
system 
Crystallisation 
technique 
Product 
3,5-lutidine 55; 45 1:6 
Methanol/ 
hexane 
Layering none 
2,4-lutidine 54; 45 1:6 
Methanol/ 
hexane 
Layering none 
2,6-lutidine 52; 45 1:6 
Methanol/ 
hexane 
layering none 
3,4-lutidine 50; 44 1:6 DMF Slow evaporation none 
3,5-lutidine 55; excess - DMF Slow evaporation none 
2,3-lutidine 58; excess - - Slow evaporation none 
2,4-lutidine 68; 55 1:6 DMF Slow evaporation none 
2,6-lutidine 53; 41 1:6 DMF Slow evaporation none 
2-picoline neat - - Slow evaporation none 
3-picoline neat - - Slow evaporation none 
4-picoline neat - - Slow evaporation none 
pyridine neat - - Slow evaporation none 
2,6-diaminopyridine 53; 41 1:6 DMF slow evaporation none 
piperazine 71; 50 1:6 THF slow evaporation none 
2,3-lutidine 52; 42 1:6 DMF Slow evaporation none 
2,5-lutidine 58; 46 1:6 DMF Slow evaporation none 
3,5-lutidine 52; 42 1:6 DMF Slow evaporation none 
2-picoline 50; 38 1:6 DMF Slow evaporation none 
3-picoline 54; 34 1:6 DMF Slow evaporation none 
4-picoline 50; 46 1:6 DMF Slow evaporation none 
pyridine 56; 35 1:6 DMF Slow evaporation none 
4,4'-bipyridine 58; 60 1:6 DMF Slow evaporation none 
4,4'-trimethylene 
dipyridine 
50; 90 1:6 DMF Slow evaporation none 
piperazine 57; 39 1:6 DMF Slow evaporation none 
2,6-diaminopyridine 65; 50 1:6 THF Slow evaporation none 
thiourea 101; 58 1:6 THF Slow evaporation none 
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Table S13 Summary of crystallisation experiments with 9 in a range of solvents and with a series of 
potential co-crystal formers. 
Co-former 
Quantity (9; 
co-former) /mg 
Mole ratio (9: 
co-former) 
Solvent system 
Crystallisation 
technique 
Product 
imidazole 100; 25 1:3 THF Inert (under N2) none 
benzimidazole 109; 46 1:3 THF Inert (under N2) none 
4,4'-bipyridine 118; 57 1:3 THF Inert (under N2) none 
2-aminopyridine 106; 35 1:3 THF Inert (under N2) none 
urea 98; 22 1:3 THF/acetonitrile Inert (under N2) none 
pyridine 118; 34 1:3 THF Inert (under N2) none 
3,4-lutidine 118; 40 1:3 THF Inert (under N2) none 
4-picoline 99; 32 1:3 THF Inert (under N2) none 
2,6-
diaminopyridine 
120; 41 1:3 THF Inert (under N2) none 
benzonitrile 161 As solvent - Inert (under N2) none 
2-cyanopyridine 135; 56 1:3 THF Inert (under N2) crystals of 9 
3-cyanopyridine 109; 55 1:3 THF Inert (under N2) none 
4-cyanopyridine 140; 44 1:3 THF Inert (under N2) none 
fluorophenol 50; 37 1:3 Acetonitrile/DCM Slow evaporation none 
1,4-
difluorobenzene 
48; 22 1:3 acetonitrile Slow evaporation none 
1,3-
dibromobenzene 
48; 48 1:3 acetonitrile Slow evaporation none 
4-
bromobenzonitril
e 
54; 35 1:3 Acetonitrile/DCM Slow evaporation crystals of 9 
4-chlorotoluene 51; 28 1:3 acetonitrile Slow evaporation none 
4-iodoaniline 53; 44 1:3 Acetonitrile/DCM Slow evaporation none 
3-bromopyridine 52; 36 1:3 acetonitrile Slow evaporation none 
3-bromoanisol 50; 19 1:1 acetonitrile Slow evaporation none 
-dibromo-p-
xylene 
51; 23 1:1 Acetonitrile/DCM Slow evaporation crystals of 9 
-dibromo-m-
xylene 
52; 21 1:1 Acetonitrile/DCM Slow evaporation none 
-dibromo-o-
xylene 
51; 18 1:1 Acetonitrile/DCM Slow evaporation crystals of 9 
3-
bromobenzotriflu
oride 
52; 20 1:1 acetonitrile Slow evaporation none 
1,2-
dichlorobenzene 
52; 18 1:1 acetonitrile Slow evaporation none 
imidazole 61; 10 1:3 THF Slow evaporation crystals of 9 
benzimidazole 60; 19 1:3 THF Slow evaporation none 
4,4'-bipyridine 60; 23 1:3 THF Slow evaporation none 
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Table S13 (continued) 
Co-former 
Quantity (9; 
co-former) /mg 
Mole ratio (9: 
co-former) 
Solvent system 
Crystallisation 
technique 
Product 
4,4'-trimethylene 
dipyridine 
64; 35 1:3 THF 
Slow 
evaporation 
none 
2-
aminopyrimidine 
61; 17 1:3 THF 
Slow 
evaporation 
none 
pyridine 62; 19 1:3 THF 
Slow 
evaporation 
crystals of 9 
3,4-lutidine 61; 17 1:3 THF 
Slow 
evaporation 
crystals of 9 
4-picoline 61; 16 1:3 THF 
Slow 
evaporation 
crystals of 9 
benzonitrile 62; 18 1:3 THF 
Slow 
evaporation 
none 
2-cyanopyridine 62; 22 1:3 THF 
Slow 
evaporation 
none 
3-cyanopyridine 61; 17 1:3 THF 
Slow 
evaporation 
none 
4-cyanopyridine 65; 20 1:3 THF 
Slow 
evaporation 
none 
cobalt(II)acetate 60; 20 1:1 THF/MeOH Layered crystals of 9 
copper(II)acetate 62; 34 1:1 THF/MeOH Layered crystals of 9 
 
Table S14 Summary of crystallisation experiments with 10 in a range of solvents and with a series of 
potential co-crystal formers. 
Co-former 
Quantity 
(10; co-
former) 
/mg 
Mole ratio 
(10: co-
former) 
Solvent system 
Crystallisation 
technique 
Product 
imidazole 56; 12 1:3 THF Slow evaporation crystals of 10 
benzimidazole 50; 13 1:3 THF Slow evaporation crystals of 10 
-dibromo-p-xylene 51; 30 1:3 THF/DCM Slow evaporation none 
-dibromo-o-xylene 53; 34 1:3 THF/DCM Slow evaporation crystals of 10 
4-bromobenzonitrile 50; 21 1:3 THF/DCM Slow evaporation none 
3,4-lutidine 53; 14 1:3 DCM Slow evaporation none 
pyridine 51; 14 1:3 THF Slow evaporation none 
cobalt(II)acetate 48; 15 1:1 THF/MeOH Layered  none 
copper(II)acetate 54; 12 1:1 THF/MeOH Layered none 
hexakis(4-
fluorophenoxy)cyclo-
triphosphazene 
28; 24 1:1 THF Slow evaporation none 
hexakis(4-
bromophenoxy)cyclo-
triphosphazene 
26; 33 1:1 THF Slow evaporation none 
phosphonitrilic 
chloride trimer 
51; 19 1:1 THF Slow evaporation none 
4-chlorophenol 57; 16 1:3 THF Slow evaporation crystals of 10 
iodopentafluoroben-
zene 
52; 18 1:1 
Chloroform/aceto
-nitrile 
Vapour diffusion 
(AcCN) 
crystals of 10 
bromopentafluoroben-
zene 
50;24 1:1 
Chloroform/aceto
-nitrile 
Vapour diffusion 
(AcCN) 
crystals of 10 
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Table S15 Summary of crystallisation experiments with 11 in a range of solvents and with a series of 
potential co-crystal formers. 
Co-former 
Amount 
(11; co-
former) in 
mg 
Ratio (11: 
co-
former) 
Solvent 
system 
Crystallisation 
technique 
Product 
hexakis(4-
fluorophenoxy)cyclo-
triphosphazene 
63; 41 1:1 THF Slow evaporation crystals of 11 
hexakis(4-iodophenoxy)-
cyclotriphosphazene 
65; 78 1:1 THF Slow evaporation none 
imidazole 62; 10 1:3 THF Slow evaporation crystals of 11 
-dibromo-p-xylene 63; 30 1:3 THF/DCM Slow evaporation 
-dibromo-p-
xylene 
-dibromo-o-xylene 64; 36 1:3 THF/DCM Slow evaporation none 
4-bromobenzonitrile 63; 29 1:3 THF/DCM Slow evaporation crystals of 11 
cobalt(II)acetate 60; 18 1:2 THF/MeOH Layered  crystals of 11 
copper(II)acetate 60; 12 1:2 THF/MeOH Layered  crystals of 11 
3,4-lutidine 61; 14 1:3 THF Slow evaporation crystals of 11 
pyridine 62; 17 1:3 THF Slow evaporation crystals of 11 
5 68; 39 1:1 THF Slow evaporation crystals of 11 
phosphonitrilic chloride 
trimer 
65; 18 1:1 THF Slow evaporation crystals of 11 
bromopentafluoroben-
zene 
54; 18 1:1 
Chloroform/
acetonitrile 
Vapour diffusion 
(AcCN) 
crystals of 11 
iodopentafluorobenzene  52; 14 1:1 
Chloroform/
acetonitrile 
Vapour diffusion 
(AcCN) 
crystals of 11 
bromopentafluorobenzene 51; 52 1:4 
Chloroform/
acetonitrile 
Vapour diffusion 
(AcCN) 
crystals of 11 
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Table S16 Summary of crystallisation experiments with 12 in a range of solvents and with a series of 
potential co-crystal formers. 
Co-former 
Quantity 
(12; co-
former) 
/mg 
Mole ratio 
(12: co-
former) 
Solvent 
system*
 
Crystallisation 
technique 
Product 
4-iodoaniline 61; 32 1:3 DCM 
Slow 
evaporation 
crystals of 12 
acetonitrile 59 excess 
DCM/ 
acetonitrile
 
Slow 
evaporation 
none 
4-bromobenzonitrile 62; 26 1:3 DCM
 Slow 
evaporation 
crystals of 12 
1,3-dicyanobenzene 62; 19 1:3 DCM
 Slow 
evaporation 
crystals of 12 
2-cyanopyridine 59; 16 1:3 DCM 
Slow 
evaporation 
none 
3-cyanopyridine 61; 16 1:3 DCM 
Slow 
evaporation 
none 
4-cyanopyridine 65; 22 1:3 DCM 
Slow 
evaporation 
crystals of 12 
4-iodobenzonitrile 64; 31 1:3 DCM 
Slow 
evaporation 
none 
benzonitrile 63; 16 1:3 DCM 
Slow 
evaporation 
crystals of 12 
nitrobenzene 66; 26 1:3 DCM 
Slow 
evaporation 
none 
o-tolunitrile 65; 21 1:3 DCM 
Slow 
evaporation 
none 
m-tolunitrile 61; 22 1:3 DCM 
Slow 
evaporation 
none 
p-tolunitrile 61; 19 1:3 DCM 
Slow 
evaporation 
none 
iodophenol 60; 32 1:3 DCM/THF 
Slow 
evaporation 
crystals of 12 
1,2-bis(2-pyridyl)ethylene 65; 25 1:3 DCM/THF 
Slow 
evaporation 
crystals of 12 
4,4’-diiodobiphenyl 67; 51 1:3 DCM 
Slow 
evaporation 
none 
1,4-diiodobenzene 64; 46 1:3 DCM 
Slow 
evaporation 
none 
2-iodopropane 62; 24 1:3 DCM 
Slow 
evaporation 
none 
propionitrile 64; 13 1:3 DCM 
Slow 
evaporation 
none 
terephthalonitrile 64; 19 1:3 
DCM/ 
acetonitrile 
Slow 
evaporation 
crystals of 12 
4-(4-
fluorophenyl)benzonitrile 
62; 26 1:3 DCM 
Slow 
evaporation 
none 
hexakis(4-
fluorophenoxy)cyclotri-
phosphazene 
66; 38 1:1 Chloroform 
Slow 
evaporation 
crystals of 12 
and 9 
iodopentafluorobenzene 51; 11 1:1 
Chloroform/ 
acetonitrile 
Vapour diffusion 
(AcCN) 
crystals of 12 
iodopentafluorobenzene 51; 50 1:4 
Chloroform/ 
acetonitrile 
Vapour diffusion 
(AcCN) 
crystals of 12 
bromopentafluorobenzene 50; 24 1:1 
Chloroform/ 
acetonitrile 
Vapour diffusion 
(AcCN) 
crystals of 12 
*
These crystallisations were also repeated in chloroform
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Table S17 Crystallisations from the melt with 9, 10, 11 and 12 in a 1:1 mole ratio 
Compound 1 Compound 2 
Amount (cmp 1; 
cmp 2) /mg 
Method 
hexakis(4-fluorophenoxy)-
cyclotriphosphazene 
hexakis(4-chlorophenoxy)-
cyclotriphosphazene 
46; 52 Ground together & melted 
hexakis(4-fluorophenoxy)-
cyclotriphosphazene 
hexakis(4-bromophenoxy)-
cyclotriphosphazene 
45; 68 Ground together & melted 
hexakis(4-fluorophenoxy)-
cyclotriphosphazene 
hexakis(4-iodophenoxy)-
cyclotriphosphazene 
42; 82 Ground together & melted 
hexakis(4-chlorophenoxy)-
cyclotriphosphazene 
hexakis(4-bromophenoxy)-
cyclotriphosphazene 
39; 53 Ground together & melted 
hexakis(4-chlorophenoxy)-
cyclotriphosphazene 
hexakis(4-iodophenoxy)-
cyclotriphosphazene 
41; 66 Ground together & melted 
hexakis(4-iodophenoxy)-
cyclotriphosphazene 
hexakis(4-bromophenoxy)-
cyclotriphosphazen 
51; 41 Ground together & melted 
 
 
Figure S6 DSC analysis of the monoclinic form of hexakis(4-fluorophenoxy)cyclotriphosphazene (9), 
with a melt at 128.4 °C and a recrystallization event upon cooling at 53.6 °C. This structure undergoes 
single-crystal to single-crystal polymorphic transitions where 9 (the monoclinic P form) converts to 
9 between 115 and 125 °C before melting. 
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Figure S7 DSC analysis of the triclinic form of hexakis(4-fluorphenoxy)cyclotriphosphazene (9). The 
triclinic form (9) converts to 9 around 100 °C before the melt at 129.5 °C. 
 
 
Figure S8 DSC analysis of hexakis(4-chlorophenyl)cyclotriphosphazene (10), with a melt occurring at 
152.0 °C. 
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Figure S9 DSC analysis of hexakis(4-bromophenyl)cyclotriphosphazene (11), with a melt occurring at 
174.5 °C and a recrystallization event upon cooling at 92.1 °C. 
 
 
Figure S10 DSC analysis of hexakis(4-iodophenyl)cyclotriphosphazene (12), with a melt at 185.9 °C. 
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Figure S11 DSC analysis of the melt product (9/10) of the fluoro and chloro derivatives. Melting 
occurs before the melting point of the fluorophenoxy derivative (129 °C). 
 
 
Figure S12 DSC analysis of the product of 11 and 12. The melting point of 11/12 is lower than that of 
both the reagents. 
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Synthesis of 1-12 
All chemicals were purchased from Sigma-Aldrich and used without further purification. THF, 
diethylether and toluene were distilled over sodium sand or wire with benzophenone as indicator, 
under an atmosphere of dry nitrogen. DCM and acetonitrile were distilled over dried calcium hydride 
under an atmosphere of dry nitrogen. Acetone and n-hexane were distilled over dried calcium chloride 
under nitrogen. 
1
H and 
31
P NMR spectra were obtained using a 300 MHz Varian VNMRS or a 400 MHz Varian Unity 
Inova. Chemical shift values are in ppm and were referenced to either chloroform-d or DMSO-d6. Data 
for 
1
H spectra are reported as chemical shift (δ ppm) (integration, multiplicity, coupling constant 
(Hz)). H3PO4 was used as an external standard for 
31
P NMR. 
All reactions were performed under an atmosphere of dry nitrogen unless otherwise stated. 
 
Tris(1,3-diaminopropane)cyclotriphosphazene (1)
1
  
N3P3Cl6 (0.5 g,1.44 mmol) was dissolved in 50 ml of a 7:3 mixture of n-hexane:DCM. To this 
mixture, 0.8 ml (8.64 mmol) 1,3-diaminopropane was added. The reaction mixture was refluxed for 4 
hours, after which the solution was cooled and filtered and the solvent removed under reduced 
pressure. The resultant white powder was further purified by recrystallisation from methanol. Yield: 
62% (0.313 g, 0.89 mmol). 
1
H NMR (DMSO-d6, 400 MHz): δ ppm 1.53 (2H, m), 3.04 (4H, m), 3.48 (2H, s), 
31
P NMR (DMSO-d6, 
400 MHz, H3PO4): δ ppm 13.86 (d), 20.45 (t). 
Crystals of 1 were also grown from a THF/hexane solution. This proved to be the known hydrate.
1a
  
 
4,4,6,6-Tetrachloro-2,2-(biphenyl-2,2'-dioxy)cyclotriphosphazene (2)
2
 
A mixture of N3P3Cl6 (1.018 g, 2.88 mmol), 2,2'-biphenol (0.543 g, 2.88 mmol) and K2CO3 (2.013 g, 
14.4 mmol) were stirred together in 40 ml acetone at room temperature for 30 minutes. The volatiles 
were evaporated in vacuo and the residue extracted with 4 x 15 ml DCM. The solvent was evaporated 
to give a white solid, which was recrystallised from DCM/petroleum ether. Yield: 80% (1.071 g, 2.32 
mmol). Mp.: 181 – 189 °C. 
1
H NMR (CDCl3, 400 MHz): δ ppm 7.57 (2H, d, J = 7.62 Hz), 7.49 (2H, t, J = 7.42 Hz), 7.41 (2H, t, J 
= 7.62 Hz), 7.33 (2H, d, 8.01 Hz), 
31
P NMR (CDCl3, 400 MHz, H3PO4): δ ppm 21.87 (d, Cl2), 9.74 (t, 
C12O2H8). 
 
2,2-Dichloro-4,4,6,6-bis[spiro(2',2''-dioxy-1',1''-biphenylyl]cyclotriphosphazene (3)
3
 
N3P3Cl6 (2 g, 5.75 mmol), biphenyl-2,2'-diol (2.14 g, 11.51 mmol) and  K2CO3 (3.98 g, 28.77 mmol) 
were mixed in 20 ml acetone at 0 °C. The reaction mixture was stirred at room temperature for 24 
hours, and then the solvent was removed in vacuo. The product was extracted by washing with 15 ml 
of DCM four times, filtering each time with a cannula filter. The solvent was then removed under 
vacuum, yielding a white powder. Yield: 86% (2.847 g, 4.96 mmol). Mp.: 268 – 275 °C. 
1
H NMR (CDCl3, 300 MHz): δ ppm 7.55 (4H, d, J = 7.63 Hz), 7.46 (4H, d, J = 7.63 Hz), 7.36 (8H, m), 
31
P NMR (CDCl3, 300 MHz, H3PO4): δ ppm 19.79 (d, C12O2H8), 29.19 (dd, Cl2). 
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Tris(2,2'-dioxybiphenyl)cyclotriphosphazene (4)
4
 
N3P3Cl6 (1.003 g, 2.88 mmol), 2,2'-biphenol (1.815 g, 9.66 mmol) and  K2CO3 (3.010 g, 21.8 mmol) 
were refluxed for 7 hours in 140 ml acetone. The solvent was evaporated in vacuo and the residue 
washed with 100 ml water, 100 ml aqueous NaOH (0.5 M), 2 x 50 ml water, 50 ml ethanol and 50 ml 
ether. The white product was dried under vacuum. Yield: 75% (1.278 g, 1.86 mmol). Mp.: >350 °C. 
1
H NMR (CDCl3, 400 MHz): δ ppm 7.52 (2H, d, J = 7.62 Hz), 7.41 (4H, m), 7.33 (2H, t, J = 7.642 
Hz), 
31
P NMR (CDCl3, 400 MHz, H3PO4): δ ppm 26.27 (s). 
2,2-Bis(4-formylphenoxy)-4,4,6,6-bis[spiro(2',2''-dioxy-1',1''-biphenylyl]cyclotriphosphazene (5)
3
 
Compound 3 (2 g, 3.48 mmol), 4-hydroxybenzaldehyde (0.854 g, 6.96 mmol) and K2CO3 (2.663 g, 
19.28 mmol) were added to 20 ml THF at 0 °C. The mixture was refluxed for 5 hours and the solvent 
removed under vacuum. The resulting solid was extracted with DCM (4 x 10 ml), and the solvent 
subsequently removed under vacuum. The product was recrystallised from acetone. Yield: 72% 
(1.881 g, 2.52 mmol). Mp.: 220 – 224 °C 
1
H NMR (CDCl3, 300 MHz): δ ppm 7.07 (2H, d, J = 7.80 Hz), 7.31 – 7.41 (4H, m), 7.54 (4H, t, J = 
8.58 Hz), 7.96 (2H, d, 8.19 Hz), 10.01 (1H, s) 
31
P NMR (CDCl3, 300 MHz, H3PO4): δ ppm 9.62 – 
11.69 (tt), 25.59 – 26.71 (dt). 
 
Hexakis(4-cyanophenoxy)cyclotriphosphazene (6)
5
 
A mixture of 4-cyanophenol (2.071 g, 17.28 mmol) and  K2CO3 (4.804 g, 34.56 mmol) was prepared 
in 80 ml THF. N3P3Cl6 (1.030 g, 2.88 mmol) in 15 ml THF was added dropwise to this mixture. The 
reaction mixture was refluxed for 6 hours with vigorous stirring. The solvent was removed in vacuo 
and the residue dispersed in 100 ml water. The resultant white solid was separated by filtration and 
allowed to dry. Yield: 94 % (2.284 g, 2.707 mmol). Mp.: 263 – 265 °C. 
1
H NMR (DMSO-d6, 400 MHz): δ ppm 7.16 (2H, d, 8.79 Hz), 7.82 (2H, d, 8.79 Hz), 
31
P NMR 
(DMSO-d6, 400 MHz, H3PO4): δ ppm 8.51 (s). 
 
Hexakis(4-pyridyloxy)cyclotriphosphazene (7)
6
 
4-hydroxypyridine (0.826 g, 8.64 mmol) and K2CO3 (1.818 g, 12.96 mmol) were added to 50 ml THF. 
N3P3Cl6 (0.503 g, 1.44 mmol) was added to this mixture, which was then stirred for two and a half 
days at room temperature, after which it was refluxed for approximately 6 hours. The solvent was 
removed under vacuum and the residue washed with 100 ml water. The product was isolated by 
filtration and dried in vacuo to yield a light yellow product. Yield: 89% (0.897 g, 1.28 mmol). Mp.: 
163 – 165 °C. 
1
H NMR (CDCl3, 400 MHz): δ ppm 6.93 (2H, d, 6.44 Hz), 8.50 (2H, d, 6.25 Hz), 
31
P NMR (CDCl3, 
400 MHz, H3PO4): δ ppm 7.30 (s). 
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Hexakis(4-hydroxyphenoxy)cyclotriphosphazene (8)
7
 
Hexakis(4-methoxyphenoxy)cyclotriphosphazene 
A suspension of sodium 4-methoxyphenoxide was prepared in 20 ml dry THF by allowing 4-
methoxyphenol (4.274 g, 34.5 mmol) to react with NaH (1.385 g as a 60 % dispersion in mineral oil; 
equivalent to 0.828 g, 34.5 mmol pure NaH). The NaH was washed with dry petroleum ether to 
remove the mineral oil prior to use. A solution of N3P3Cl6 (2 g, 5.75 mmol) in 20 ml THF was added 
dropwise to this suspension. On complete addition of the phosphonitrilic chloride trimer, the reaction 
mixture was refluxed for 24 hours with stirring. The reaction mixture was cooled and washed with 100 
ml water in order to precipitate the product as a white powder. Yield: 82% (4.136 g, 4.733 mmol). 
Mp.: 105 – 106 °C 
1
H NMR (CDCl3, 400 MHz): δ ppm 3.72 (3H, s), 6.77 (4H, s) 
Hexakis(4-hydroxyphenoxy)cyclotriphosphazene (8) 
Hexakis(4-methoxyphenoxy)-cyclotriphosphazene (3 g, 3.43 mmol) was dissolved in 30 ml DCM. A 
solution of BBr3 (2 ml, 20.6 mmol) in 30 ml DCM was added dropwise to the solution of 
cyclotriphosphazene. The solution was allowed to stir for 3 hours, after which it was poured carefully 
into 100 ml of water to precipitate the product. The white precipitate was filtered off, washed with 
water and dried. Yield: 85% (2.303 g, 2.92 mmol). 
1
H NMR (DMSO-d6, 400 MHz): δ ppm 6.59 (2H, s), 6.61 (2H, s), 
31
P NMR (DMSO-d6, 400 MHz, 
H3PO4): δ ppm 22.32 (s). 
 
Hexakis(4-fluorophenyl)cyclotriphosphazene (9)
8,9 
This synthetic procedure was not performed under inert conditions. 
4-fluorophenol (1.94 g, 17.28 mmol) and N3P3Cl6 (0.998 g, 2.88 mmol) were dissolved in 60 ml 
acetone. K2CO3 (4.797 g, 120.96 mmol) was added to this mixture, and the reaction mixture was 
refluxed for 12 hours. The precipitate was filtered off, washed with DCM and combined with the 
filtrate. The solvent was then removed in vacuo. The white powder thus obtained was recrystallised 
from methanol. Yield: 65% (3.131 g, 3.91 mmol). Mp. 129 °C 
1
H NMR (CDCl3, 400 MHz): δ ppm 6.88 (2H, s), 6.9 (2H, s), 
31
P NMR (CDCl3, 400 MHz, H3PO4): δ 
ppm 9.86 (s). 
 
Hexakis(4-chlorophenyl)cyclotriphosphazene (10)
8
 
4-chlorophenol (2.240 g, 17.28 mmol) and K2CO3 (4.793 g, 34.56 mmol) were stirred together in 50 
ml acetone. N3P3Cl6 (1.004 g, 2.88 mmol) dissolved in 10 ml acetone was added to the mixture, which 
was then refluxed for 1 day. The solvent was removed under vacuum and the product extracted with 
DCM. The product was further purified by recrystallisation from acetonitrile. Yield: 76 % (1.982 g, 
2.2 mmol). Mp. 152 °C  
1
H NMR (CDCl3, 400 MHz): δ ppm 6.68 (2H, d, 8.20 Hz), 7.17 (2H, d, 8.40 Hz), 
31
P NMR (CDCl3, 
400 MHz, H3PO4): δ ppm 9.59 (s). 
 
 
S25 
 
Hexakis(4-bromophenyl)cyclotriphosphazene (11)
8
 
4-bromophenol (3.030 g, 17.28 mmol) and K2CO3 (4.779 g, 34.56 mmol) were added to 50 ml 
acetone. N3P3Cl6 (1.011 g, 2.88 mmol) in 10 ml acetone was added to the mixture, which was then 
refluxed for 2 days. The solvent was removed under vacuum and the product purified by 
recrystallisation from acetonitrile. Yield: 79 % (2.684 g, 2.3 mmol). Mp. 176.8 °C. 
1
H NMR (CDCl3, 400 MHz): δ ppm 6.75 (2H, d, 8.79 Hz), 7.33 (2H, d, 8.89 Hz), 
31
P NMR (CDCl3, 
400 MHz, H3PO4): δ ppm 9.29 (s). 
 
Hexakis(4-iodophenyl)cyclotriphosphazene (12)
8
 
4-iodophenol (3.844 g, 17.28 mmol) and N3P3Cl6 (1.007 g, 2.88 mmol) were dissolved in 75 ml 
acetone. K2CO3 (4.821 g, 34.56 mmol) was added to this mixture, which was refluxed for 2 days. The 
solvent was evaporated under vacuum and the product was extracted with 3 x 20 ml DCM. The 
product was further purified by recrystallisation from acetonitrile. Yield: 65% (2.702 g, 1.86 mmol). 
Mp. 187.6 °C. 
1
H NMR (CDCl3, 400 MHz): δ ppm 6.62 (2H, d, J = 8.79 Hz), 7.52 (2H, d, 8.79 Hz), 
31
P NMR 
(CDCl3, 400 MHz, H3PO4): δ ppm 9.27 (s). 
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